Jiyi Choi, Moon Gyeong Yoon, Se Ha Jang, Geum Ok Baek, Hyun Sun Jung, Na-Rae Lee, Choong Hwan Lee, Ji Eun Han, Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim
Clin Mol Hepatol 2026;32(1):239-257. Published online October 27, 2025
Background/Aims Gut microbiome plays a pivotal role in metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis, yet, associated functional mechanisms and host responses of specific microbial species remain insufficiently characterized. This study investigated the Bacteroides eggerthii therapeutic effects on MASLD by integrating multi-omics analysis and experimental validation in a Western diet (WD)-induced mouse model.
Methods Candidate strains were identified using 16S rRNA gene sequencing of fecal samples from individuals with and without MASLD or obesity. B. eggerthii, a species significantly depleted in both groups, was selected for functional evaluation. Male C57BL/6J mice were fed a WD or WD supplemented with B. eggerthii (WD+B) for 12 weeks. Liver histology, serum biochemistry, fecal microbiome and metabolome profiling, and hepatic and intestinal transcriptomic analyses were performed. Anti-steatotic effects of B. eggerthii–derived metabolites were validated in vitro.
Results Bacteroides eggerthii supplementation significantly improved liver weight, inflammation, fibrosis, and steatosis in WD+B group compared to WD alone. PICRUSt-based LEfSe analysis revealed choloylglycine hydrolase activity enrichment in gut microbiota, and strain-specific qPCR confirmed colonization in mouse colon. Integrated transcriptomic analyses revealed lipid and bile acid signaling pathway restoration, including CD36, FXR, and FGF15. Untargeted metabolomics identified elevated 2-hydroxyisocaproic acid (HICA) as a strain-derived metabolite in feces and B. eggerthii culture supernatants. In vitro, HICA significantly reduced lipid accumulation in free fatty acid-induced steatosis models.
Conclusions Bacteroides eggerthii ameliorates MASLD via gut-liver axis modulation, including bile acid metabolism and hepatic lipid signaling. These underscore its therapeutic potential and highlight HICA as a novel microbiome-derived metabolite with anti-steatotic activity.
Citations
Citations to this article as recorded by
Letter to the Editor: Circadian and microbial misalignment in metabolic dysfunction-associated steatotic liver disease - mechanistic insights and chronotherapeutic potential Christos Savvidis, Ioannis Ilias World Journal of Experimental Medicine.2026;[Epub] CrossRef
Decoding the Gut–Fat–Heart Axis: From Molecular Communication Networks to Clinical Translation Strategies Zijin Sun, Wei Shao, Haojia Zhang, Kai Wang, Yongchao Liu, Rui Zhou International Journal of Molecular Sciences.2026; 27(12): 5596. CrossRef
The gut microbiota significantly influences hepatobiliary cancer therapeutics. Growing evidence indicates that shifts in the gut microbial ecosystem are hallmarks of hepatocellular carcinoma and cholangiocarcinoma, strongly correlating with tumor development, therapeutic resistance, and patient survival. The composition of gut microbiota has emerged as a biomarker associated with treatment outcomes across various modalities, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Beneficial bacterial communities enhance antitumor immunity, while pathogenic taxa are linked to reduced therapeutic efficacy. Multi-omics analyses have identified microbial metabolite signatures, such as short-chain fatty acids and bile acids, as potential targets for boosting antitumor responses. This review highlights the transformative potential of leveraging the gut microbiota to enhance precision oncology in hepatobiliary cancer. Future directions should prioritize personalized microbiota modulation approaches, combinatorial therapies targeting gut-liver axis crosstalk, and large-scale validation of microbial biomarkers across diverse populations.
Citations
Citations to this article as recorded by
Liver Transplantation Following Immune Checkpoint Inhibitor Therapy: What Do We Need to Know from Clinical and Immunological Perspective? Hee Sun Cho, Soon Kyu Lee International Journal of Molecular Sciences.2026; 27(6): 2680. CrossRef
Dental prophylactic interventions are associated with lower decompensation-related hospitalizations over 2 years in cirrhosis Jasmohan S. Bajaj, Scott Silvey, Anas Aljabi, Janina Golob Deeb, Nilang Patel JHEP Reports.2026; 8(5): 101821. CrossRef
Multidimensional Regulatory Networks of Immune Resistance in Intrahepatic Cholangiocarcinoma: Synergistic Mechanisms of Tumor Microenvironment, Immune Cells, and Microbiota, and Novel Therapeutic Strategies Lingyu Kong, Hongxin Piao Gastrointestinal Disorders.2026; 8(3): 32. CrossRef
Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, has become the most common form of chronic liver disease in children. The spectrum of pediatric MASLD ranges from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and in rare cases, hepatocellular carcinoma. Its pathogenesis involves a complex interplay among genetic, epigenetic, and environmental factors, along with alterations in the gut microbiota and its associated metabolites. Given the staggering prevalence and the distinct etiopathogenesis of pediatric MASLD, characterization of the gut microbiota and microbial products could facilitate the development of diagnostic tools and inform targeted therapeutic strategies. Current research on the gut microbiome in the context of pediatric MASLD is limited by small sample size, inadequate use of liver biopsy, methodological inconsistencies in sequencing, and confounding effects from metabolic comorbidities. In this review, we summarize clinical studies on alterations in the gut microbiota and microbial products (short-chain fatty acids, bile acids, and ethanol) that impact the pathogenesis of pediatric MASLD. We discuss the therapeutic potential of dietary modification, pharmacological treatments, and probiotics in improving disease progression by summarizing current clinical studies. Enhancing our understanding of the gut-liver axis may aid in the development of effective therapeutic strategies for pediatric MASLD.
Citations
Citations to this article as recorded by
Obesity, Metabolic Syndrome and MASLD in Children: Inflammation as the Missing Link—A Short Narrative Review Mihaela-Andreea Podeanu, Claudiu Marinel Ionele, Raluca Elena Sandu, Ion Rogoveanu, Mioara Desdemona Stepan, Carmen Elena Niculescu, Sergiu-Marian Cazacu, Ștefănița Bianca Vintilescu Life.2026; 16(2): 310. CrossRef
Artificial intelligence for metabolic dysfunction-associated steatotic liver disease diagnosis: A systematic review Ruijuan Wang, Chang Liu, Mei Xue, Jun Qian, Yue Hu Computers in Biology and Medicine.2026; 208: 111619. CrossRef
Effects of metabolic syndrome on pulmonary infection in pediatric bronchial asthma: a narrative review Li He, Yang Ye Frontiers in Pediatrics.2026;[Epub] CrossRef
Microbial metabolites at the nexus of gut-brain communication and neurodevelopmental disorders Yupeng Lai, Ming Zhang, Dandan Lang, Enfu Tao Frontiers in Nutrition.2026;[Epub] CrossRef
Targeting the Human Gut Microbiota—Between Conventional Therapy and Precision Genetic Engineering Naomi-Adina Ciurea, Laura Mahdi, Annarita Graziani, Agostino Di Ciaula, Piero Portincasa, Mohamad Khalil Nutrients.2026; 18(12): 1958. CrossRef
Gut Microbiota–Metabolite Alterations Associated with Early Metabolic Dysfunction and Hepatic Steatosis in Adolescents Natalia Zeber-Lubecka, Paweł Czarnowski, Joanna Ziemska-Legięcka, Aldona Wierzbicka-Rucińska, Wojciech Jańczyk, Jacek Michałkiewicz, Łukasz Obrycki, Mieczysław Litwin, Michał Mikula, Piotr Socha, Jerzy Ostrowski Computational and Structural Biotechnology Journal.2026;[Epub] CrossRef
The role of the gut microbiome in the development and progression of liver cancer has long been recognized. However, the presence of microbes in tumors that were previously considered sterile has only recently been discovered. The intratumor microbiome in liver cancer likely originates from various sources, including the gut, hematogenous spread from other mucosal locations, adjacent non-cancerous tissues, and co-metastasis with the tumor cells. As a newly discovered component of the tumor microenvironment, it regulates host immune responses, promotes chronic inflammation, modulates metabolic pathways, and exerts other influences in liver cancer. These unique features offer potential new biomarkers for liver cancer prognosis and treatment response. Exploring the complex interactions between intratumor microbiome and the host to modulate or target the intratumor microbiome may provide new avenues for liver cancer treatment. This article provides a comprehensive review of our current understanding regarding the potential origins of the intratumor microbiome in liver cancer, its unique characteristics, and the underlying mechanisms by which it affects liver cancer. Furthermore, we discuss the promising clinical implications and potential challenges that remain before this knowledge can be fully integrated into clinical practice.
Citations
Citations to this article as recorded by
Intratumoral Microbe Correlated with Expression of DNA Methylation Genes in Hepatocellular Carcinoma Ashish Kumar, Ajeet Raj, Karan Chaman Lal, Puja Digestive Diseases and Sciences.2026; 71(2): 737. CrossRef
Emerging technologies and current challenges in intratumoral microbiota research Zhiyue Wang, Tianqi Zhang, Yang Liu Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Microbial dysbiosis in cholangiocarcinoma Yunjia Liu, Shaohui Huang, Yang Zhang, Yuankun Zhang, Yunfei Xu, Yongchang Tang, Sen Guo, Zongli Zhang Frontiers in Microbiology.2026;[Epub] CrossRef
Mucosal immunity in cancer metastasis: roles, mechanisms, and therapeutic implications Yaru Miao, Dongdong Cui, Yanghui Bi, Ruiping Zhang Frontiers in Immunology.2026;[Epub] CrossRef
A Microbial Lipid‐ATP Synthase Axis Fuels NK Cell Antitumor Activity Kaiyuan Yu, Xinyu Sun, Wanxia Ma, Jianming Yang, Xuan Sun, Lisong Zhang, Yumeng Liu, Tianshu Ren, Qi Wang, Jingyu Wang, Xiao Li, Xianping Peng, Liu Yang, Junqiang Lv, Zhi Yao, Zhi‐Song Zhang, Quan Wang Advanced Science.2026;[Epub] CrossRef
The intratumoral microbiota: Orchestrating metabolic-immune crosstalk and shaping the therapeutic landscape in cancer Shilin Wang, Ziyi Liu, Chunyun Jiang, Yanting Wei, Guohong Liu, Yunbao Pan Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2026; 1872(7): 168316. CrossRef
Gut‐Liver Translocation of Bacteroides Uniformis Alleviates Advanced Metabolic Dysfunction‐Associated Steatotic Liver Disease by Suppressing Hepatocyte Ferroptosis via Propionic Acid Secretion Haiyang Liu, Zun Fan, Zhen Liu, Lei Qin, Xin Zhao Advanced Science.2026;[Epub] CrossRef
RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond You-Peng Ding, Cui-Cui Liu, Ke-Da Yu Experimental Hematology & Oncology.2025;[Epub] CrossRef
Unveiling hidden players: the role of intratumoral microbiota in gastrointestinal cancer dynamics Wanfen Tang, Fakai Li, Hongjuan Zheng, Shishi Zhou, Chenhui Li, Xifeng Xu, Jianfei Fu Journal of Cancer Research and Clinical Oncology.2025;[Epub] CrossRef
Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan
Clin Mol Hepatol 2025;31(Suppl):S94-S111. Published online November 28, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as obesity and type 2 diabetes mellitus. This spectrum of liver disease ranges from isolated steatosis to more severe forms such as steatohepatitis, fibrosis, and cirrhosis. Recent studies highlight the role of gut microbiota in MASLD pathogenesis, showing that dysbiosis significantly impacts metabolic health and the progression of liver disease. This review critically evaluates current microbiome-centered therapies in MASLD management, including prebiotics, probiotics, synbiotics, fecal microbiota transplantation, and emerging therapies such as engineered bacteria and bacteriophage therapy. We explore the scientific rationale, clinical evidence, and potential mechanisms by which these interventions influence MASLD. The gut-liver axis is crucial in MASLD, with notable changes in microbiome composition linked to disease progression. For instance, specific microbial profiles and reduced alpha diversity are associated with MASLD severity. Therapeutic strategies targeting the microbiome could modulate disease progression by improving gut permeability, reducing endotoxin-producing bacteria, and altering bile acid metabolism. Although promising, these therapies require further research to fully understand their mechanisms and optimize their efficacy. This review integrates findings from clinical trials and experimental studies, providing a comprehensive overview of microbiome-centered therapies’ potential in managing MASLD. Future research should focus on personalized strategies, utilizing microbiome features, blood metabolites, and customized dietary interventions to enhance the effectiveness of these therapies.
Citations
Citations to this article as recorded by
Probiotic-Derived Strain-Specific Metabolites Ameliorate Metabolic Dysfunction–Associated Steatotic Liver Disease through Modulation of the Gut-Liver Axis Sang Jun Yoon, Jieun Choi, Sung-Min Won, Jeong Seok Yu, Hee Young Kim, Hyun Chae Joung, In Gyu Park, Jung A Eom, Sang Hak Han, Do Yup Lee, Ki Tae Suk Probiotics and Antimicrobial Proteins.2026; 18(3): 4353. CrossRef
Sarcopenia and MASLD: novel insights and the future Chang-Hai Liu, Qing-Min Zeng, Won Kim, Seung Up Kim, Zobair M. Younossi, Giovanni Targher, Christopher D. Byrne, Christos S. Mantzoros, Phunchai Charatcharoenwitthaya, Isabelle Anne Leclercq, Manuel Romero-Gómez, Hong Tang, Ming-Hua Zheng Nature Reviews Endocrinology.2026; 22(3): 139. CrossRef
Digoxin-induced gut dysbiosis: Mechanistic links to prostaglandin dysregulation and lipid metabolic imbalance Nila Ganamurali, Sarvesh Sabarathinam Prostaglandins & Other Lipid Mediators.2026; 182: 107055. CrossRef
Guideline comparison for fatty liver disease: European (EASL-EASD-EASO) and Asian (APASL) perspectives Ludovico Abenavoli Expert Review of Gastroenterology & Hepatology.2026; 20(1): 5. CrossRef
The Metabolic Dysfunction–Associated Steatotic Liver Disease–CKD Axis: Intersecting Pathways and Opportunities for Early Intervention Sriram Sriperumbuduri, Prathab Balaji Saravanan, Gaurav Gupta, Arun J. Sanyal Kidney International Reports.2026; 11(4): 103757. CrossRef
Exercise-mimicking effects of betaine in chronic disease prevention and management Yuhui Xu, Jianhong Gao, Minghui Wang, Hu Zhang Frontiers in Nutrition.2026;[Epub] CrossRef
Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host–microbe signaling and highlights 2-hydroxyisocaproate as a potential effector Jiyi Choi, Moon Gyeong Yoon, Se Ha Jang, Geum Ok Baek, Hyun Sun Jung, Na-Rae Lee, Choong Hwan Lee, Ji Eun Han, Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim Clinical and Molecular Hepatology.2026; 32(1): 239. CrossRef
The Gut Commensal Butyricimonas Virosa Modulates Gut Microbiota‐Dependent Thiamine Metabolism and Attenuates Mouse Steatotic Liver Disease Ningning He, Haoyu Wang, Zizhen Yang, Hui Li, Bei Liu, Kaiwei Chen, Zhinan Wu, Xinnan Zhao, Hewei Liang, Mengmeng Wang, Xiaofang Li, Yiyi Zhong, Haifeng Zhang, Liang Xiao, Karsten Kristiansen, Jixing Peng, Yuanqiang Zou, Shangyong Li Advanced Science.2026;[Epub] CrossRef
The Gut–Liver Axis in MASLD: From Host–Microbiome Crosstalk to Precision Therapeutics Ji Zhou, Bowen Zhu, Ziqian Bing, Tingting Wang, Yue Zhao Microorganisms.2026; 14(2): 471. CrossRef
Therapeutic modulation of the gut-liver axis with faecalibacterium prausnitzii in metabolic dysfunction-associated steatohepatitis Han Chen, Yan Wang, Wei Su, Yicheng Liu, Shuo Li, Yun Liu, Xiaoying Zhou BMC Microbiology.2026;[Epub] CrossRef
MetALD at the crossroads of metabolic and alcohol-related liver disease Gustavo Ayares, Luis Antonio Díaz, Juan Pablo Arab, Marco Arrese Trends in Endocrinology & Metabolism.2026;[Epub] CrossRef
Prebiotic modulation of FMT donor microbiota enhances MASLD-relevant taxa and functions in an in vitro gut model Kait F Al, Suyang Jia, Michael Silverman, Gregor Reid, Jeremy P Burton, Seema Nair Parvathy Journal of Applied Microbiology.2026;[Epub] CrossRef
Association of gut microbiota dietary index with MAFLD and the risk of liver fibrosis: the mediating effect of vitamins Jinlu Han, Teng Zhou, Jiong Chen, Ling Xu, Wen Shan, Qinghui Zhang Journal of Nutritional Science.2026;[Epub] CrossRef
The Microbiome‐Gut‐Liver Axis Drives Post‐Kasai Fibrosis in Biliary Atresia: From Mechanism to Precision Intervention Jiwen Cheng Hepatology Research.2026; 56(5): 648. CrossRef
Effects of Probiotic and Synbiotic Supplementation on Metabolic and Hepatic Outcomes in Children and Adolescents With Obesity, Including Those With Obesity‐Related Metabolic Dysfunction–Associated Steatotic Liver Disease: A Systematic Review and Meta‐Anal Pedram Pam, Mohammad Safari, Ali Hojati, Rasoul Zarrin, Amir Hossein Faghfouri Journal of Paediatrics and Child Health.2026; 62(5): 678. CrossRef
Correspondence to letter to the editor on “Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease” Eiji Kakazu, Masaaki Mino, Tatsuya Kanto Clinical and Molecular Hepatology.2026; 32(2): e235. CrossRef
Gut microbiome and metabolic health: mechanisms and precision interventions Zhengrui Li, Sudeshna Samui, Ji'an Liu, Yang Yang, Xue Liu, Qingyu Chen, Jing Li, Divya Gopinath, Peng Luo, Dan Shan Gut Microbes.2026;[Epub] CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Microbial dysbiosis in metabolic disorders: linking epigenomic regulation and pathological mechanisms Arun K. Sharma, Md Sayeed Akhtar, Khalid Orayj, Sadaf Farooqui, Abida Khan, Gunjan Sharma Drug Discovery Today.2026; 31(4): 104698. CrossRef
Impact of probiotics and prebiotics on glucose/lipid metabolism in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications Yinan Zhao, Ziyan Li, Guoying Yu Frontiers in Nutrition.2026;[Epub] CrossRef
Maternal-Infant Gut Microbiota Transmission and the Early Origins of Metabolic Liver Diseases: Mechanisms and Interventional Opportunities Xinrui Meng, Xueping Wu, Huihui Sun, Jing Cong, Yuchao Gu Nutrition Reviews.2026;[Epub] CrossRef
The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets Poonam Sahu, Trilochan Satapathy Probiotics and Antimicrobial Proteins.2026;[Epub] CrossRef
Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation Carlo Acierno, Alfredo Caturano, Fannia Barletta, Luca Rinaldi, Ferdinando Carlo Sasso, Luigi Elio Adinolfi, Riccardo Nevola Nutrients.2026; 18(11): 1765. CrossRef
Structural characterization of the pectic polysaccharide from corn silk and its protective mechanism against MASLD via regulation of the gut-liver axis Haichao Wang, Jiajing Yan, Haolin Jia, Xiaoyan Li, Bingxuan Li, Xuefang Zhang, Shujun Wang, Zheng Li, Yuhong Liu, Yifei Bian Carbohydrate Polymers.2026; 388: 125510. CrossRef
Association between oral microbiome alpha and beta diversity and MASLD risk: a large-scale, population-based retrospective study Zeru Liu, Yizhi Mao, Lei Zhang, Beibei Wang, Jiaxuan Tian, Yanjun Li, Shuangshuang Li, Yinglong He, Meiyan Zeng, Pan Meng, Houpan Song Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Microbiome‐Derived Metabolite Networks in Metabolic Dysfunction‐Associated Fatty Liver Disease: Mechanistic Integration of Gut‐Liver Axis Signaling and Therapeutic Targeting Adhiyaman Muniraj, Shreshta Vidhya Elango, Mahalaxmi Iyer, Mederametla Roja Rani, Saranya Vinayagam, Lalitha Gnanasekaran, Mukesh Kumar Yadav, Krothapalli Raja Surya Sambasiva Rao, Balachandar Vellingiri, Anirban Goutam Mukherjee, Raja Ganesan Comprehensive Physiology.2026;[Epub] CrossRef
Metabolic Dysfunction‐Associated Fatty Liver Disease: From Pathogenesis to Treatment Zhifu Cui, Xiaxia Du, Felix Kwame Amevor, Yaoyao Xia, You Yang, Lingbin Liu MedComm.2026;[Epub] CrossRef
Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy Young Eun Chon, Kyung‐Do Han, Ju Dong Yang, Ju‐Yeong Park, Hyun‐Seok Kim, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Association of prebiotic/probiotic intake with MASLD: evidence from NHANES and randomized controlled trials in the context of prediction, prevention, and a personalized medicine framework Senlin Wang, Ruimin Zhang, Peisen Guo, Huawu Yang, Yanjun Liu, Hongmei Zhu EPMA Journal.2025; 16(1): 183. CrossRef
Deciphering the role of dietary modifications and gut dysbiosis in Non-Alcoholic Fatty Liver Disease Meenakshi Vachher, Kohinoor Kaur, Manisha Marothia, Archana Burman, Deepanjana, Savita Bansal Human Nutrition & Metabolism.2025; 40: 200305. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso Exploration of Medicine.2025;[Epub] CrossRef
Electroacupuncture Attenuates Intestinal Barrier Disruption via the α7nAChR-Mediated HO-1/p38 MAPK/NF-κB Pathway in a Mouse Model of Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized, Single-Blind, Controlled Trial Xiao Wang, Jiasen Sun, Peng Wang, Yimin Zhang, Jiuyang Chang, Zhijun Duan Biomedicines.2025; 13(4): 802. CrossRef
Unraveling MASLD: The Role of Gut Microbiota, Dietary Modulation, and AI-Driven Lifestyle Interventions Carolina Jiménez-González, Marta Alonso-Peña, Paula Argos Vélez, Javier Crespo, Paula Iruzubieta Nutrients.2025; 17(9): 1580. CrossRef
Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies Claudia Reytor-González, Daniel Simancas-Racines, Martín Campuzano-Donoso, Janeth Castano Jimenez, Náthaly Mercedes Román-Galeano, Gerardo Sarno, Evelyn Frias-Toral Food and Agricultural Immunology.2025;[Epub] CrossRef
Gut microbiota modulation by Traditional Chinese Medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease Ting Zhou, Ziwen Jin, Rilei Jiang, Weiwei Li Frontiers in Pharmacology.2025;[Epub] CrossRef
Orchestration of Gut–Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation Ao Liu, Mengting Huang, Yuwen Xi, Xiaoling Deng, Keshu Xu Biomedicines.2025; 13(6): 1422. CrossRef
Gut microbiota in liver diseases: initiation, development and therapy Jian-Xiu Yu, Jun Wu, Xin Chen, Su-gang Zang, Xue-bin Li, Li-Pei Wu, Shi-hai Xuan Frontiers in Medicine.2025;[Epub] CrossRef
Medical Implications of Renaming Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Yu-Jin Choi, Chang-Gue Son Journal of Korean Medicine.2025; 46(2): 40. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): emerging insights into gut microbiota interactions and therapeutic perspectives Wenchu Qian, Ling He, Chenxue Fu, Tiantian Zeng, Hanyu Wang, Haifang Li Exploration of Digestive Diseases.2025;[Epub] CrossRef
Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD Zhonghao Jiang, Baolin Qian, Tongjie Xu, Junjie Bai, Wenguang Fu ImmunoTargets and Therapy.2025; Volume 14: 719. CrossRef
Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang Gut and Liver.2025; 19(4): 479. CrossRef
Association of the dietary index for gut microbiota and dietary inflammation index with metabolic dysfunction-associated steatotic liver disease and metabolic alcohol-associated liver disease Wenhao Wu, Zebin Hou Frontiers in Immunology.2025;[Epub] CrossRef
Cholesterol and the gut-liver axis: unraveling their role in the onset and progression of metabolic-associated steatotic liver disease Luis A. Rodríguez-Rojas, Leticia Bucio-Ortiz, Verónica Souza-Arroyo, María Concepción Gutiérrez-Ruiz, Luis E. Gómez-Quiroz, Roxana U. Miranda-Labra Exploration of Digestive Diseases.2025;[Epub] CrossRef
Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies Said A Al-Busafi, Ahmed Alwassief, Ali Madian, Hassan Atalla, Mohamed Alboraie, Ashraf Elbahrawy, Mohammed Eslam World Journal of Hepatology.2025;[Epub] CrossRef
Present and Future Perspectives in the Treatment of Liver Fibrosis Lucia Cerrito, Linda Galasso, Jacopo Iaccarino, Alessandro Pizzi, Fabrizio Termite, Giorgio Esposto, Raffaele Borriello, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco Pharmaceuticals.2025; 18(9): 1321. CrossRef
Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway Jianping Zhu, Yuzhen Chen, Yidi Han, Ji Li, Fahrul Nurkolis PLOS One.2025; 20(9): e0331303. CrossRef
Genome-Based Mexican Diet Bioactives Target Molecular Pathways in HBV, HCV, and MASLD: A Bioinformatic Approach for Liver Disease Prevention Leonardo Leal-Mercado, Arturo Panduro, Alexis José-Abrego, Sonia Roman International Journal of Molecular Sciences.2025; 26(18): 8977. CrossRef
Impact of non-alcoholic hepatic steatosis on prognosis and clinical outcomes in gastric cancer patients undergoing laparoscopic distal gastrectomy Yi-Fan Zou, Yi-Gang Zhang, Zi-Chu Zhao, Zheng Li, Hong-Da Liu, Qing-Ya Li, Ze-Tian Chen, Cheng-Jun Zhu, Hai-Tao Liu, Ji-Wei Wang, Feng-Yuan Li, Lin-Jun Wang, Dian-Cai Zhang, Li Yang, Hao Xu, Ze-Kuan Xu, Sen Wang World Journal of Gastrointestinal Surgery.2025;[Epub] CrossRef
Recent research advances in RNA m5C methylation modification in liver diseases Wenjuan Chen, Lifan Zhang, Xinyu Gu, Yafeng Liu, Shujun Zhang, Xinjun Hu, Penghui Li Frontiers in Molecular Biosciences.2025;[Epub] CrossRef
Integrative gut microbiota and metabolomics reveals the mechanism of chicory extract in improving metabolic dysfunction-associated steatotic liver disease via gut-liver axis Haifeng Wang, Songlin Liu, Yonggang Chen, Weiwei Fang, Ying Cheng, Zhigang Zhang, Haiming Hu, Baifei Hu, Hongtao Liu Phytomedicine.2025; 148: 157404. CrossRef
Harnessing Gut Microbiome–Brain–Liver Crosstalk: Novel Therapeutic Strategies for Metabolic Dysfunction‐Associated Steatotic Liver Disease Xingtao Zhao, Ruolan Li, Jingdong Zhao, Ruiqi Sun, Shuo Zhang, Qiong Pan, Hongyan Lu, Jin Chai Medicine Bulletin.2025; 1(2): 136. CrossRef
Honeysuckle-derived exosome-like nanovesicles ameliorate metabolic-associated fatty liver disease by modulating gut microbiota and its metabolites Ping Li, Qingyuan Wu, Yuanhao Zhou, Xiaojuan Hu, Yan Tang, Yuanyuan Wang, Weijiao Fan, Yiyi Shan, Kexin Yu, Jie Wang, Shibing Wang, Xiao Ye, Huiyu Liu, Xiaozhou Mou Nano Research.2025; 18(12): 94907986. CrossRef
Perturbed microbial ecology in pediatric systemic lupus erythematosus: Evidence from the gut microbiome and serum metabolome Bo Li, Tao Ma, Yanjun Jia, Chunfeng Mou, Meng Zeng, Jie Yu, Lin Zou, Xiaoqiang Li, Han Wang Genes & Diseases.2025; : 101932. CrossRef
The Gut-Liver Axis: Molecular Mechanisms and Therapeutic Targeting in Liver Disease Liang Ma, He Wang, Qiuyu Jin, Zhiwen Sun, Shuang Yu, Yang Zhang International Journal of General Medicine.2025; Volume 18: 7531. CrossRef
Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD Xiaoxue Long, Hui Wang, Yuwei Lu, Xiaojing Gao, Yuanyuan Xiao, Mingliang Zhang, Jingyi Guo, Jingyi Yang, Ruiqi Zhang, Qian Li, Guiyun Zhou, Ruibao Yang, Feng Chen, Qingqing Wu, Liming Sun, Chengshuang Chu, Xuexue Zhu, Zhengjun Wu, Quanlu Ren, Chunping You Cell Metabolism.2025; 37(12): 2342. CrossRef
Gut microbiota in hepatic encephalopathy: a 3PM-guided three-tier health strategy Jing Chen, Mingliao Niu, Longjiang Zhang EPMA Journal.2025; 17(1): 135. CrossRef
An umbrella meta-analysis of microbial therapy on hepatic steatosis, fibrosis, and liver stiffness in metabolic dysfunction-associated steatotic liver disease Gvzalnur Kurban, Xiangjun Chen, Xingyi Jin, Hui Xia, Shaokang Wang, Guiju Sun Frontiers in Nutrition.2025;[Epub] CrossRef
Drug treatment of MASH from none to (too) many options? Amedeo Lonardo, Ralf Weiskirchen Exploration of Medicine.2025;[Epub] CrossRef
Prebiotic and Probiotic Foods in MASLD: Microbiome-Mediated Therapeutic Strategies Cui Beiming, Liu Yujie, Hui-Eun Chang Joyce, Chen Jieying, Xu Jiahang, Teoh Jian-Peng, Loong Ho Chun Synthetic Biology and Engineering.2025; 3(4): 10018. CrossRef
Background/Aims Evidence suggests that the gastrointestinal microbiome plays a significant role in the biology of metabolic dysfunction-associated steatotic liver disease (MASLD). However, it remains unclear whether disparities in the gut microbiome across intestinal tissular compartments between the sexes lead to MASLD pathogenesis.
Methods Sex-specific analyses of microbiome composition in two anatomically distinct regions of the gut, the small intestine and colon, were performed using an experimental model of MASLD. The study involved male and female spontaneously hypertensive rats and the Wistar-Kyoto control rat strain, which were fed either a standard chow diet or a high-fat diet for 12 weeks to induce MASLD (12 rats per group). High-throughput 16S sequencing was used for microbiome analysis.
Results There were significant differences in the overall microbiome composition of male and female rats with MASLD, including variations in topographical gut regions. The beta diversity of the jejunal and colon microbiomes was higher in female rats than in male rats (PERMANOVA p-value=0.001). Sex-specific analysis and discriminant features using LEfSe showed considerable variation in bacterial abundance, along with distinct functional properties, in the jejunum and colon of animals with MASLD. Significantly elevated levels of lipopolysaccharide and protein expression of Toll-like receptor 4 were observed in the livers of male rats with MASLD compared with their female counterparts.
Conclusions This study uncovered sexual dimorphism in the gut microbiome of MASLD and identified microbial heterogeneity within intestinal compartments. Insights into sex-specific variations in gut microbiome composition could facilitate customised treatment strategies.
Citations
Citations to this article as recorded by
Sex and gender differences in metabolic dysfunction-associated liver disease Rishitha Penmetsa, Sasha Kapil, Lisa B. VanWagner Indian Journal of Gastroenterology.2026; 45(2): 192. CrossRef
New Definition, New Point of View: Sex and Gender Interpretation of MASLD—Interpretation of Guidelines and Review of the Literature Massimo De Luca, Rita Verdoliva, Anna Lombardi, Antonio Giorgio Gastroenterology Insights.2026; 17(1): 7. CrossRef
The Gut–Liver Axis in MASLD: From Host–Microbiome Crosstalk to Precision Therapeutics Ji Zhou, Bowen Zhu, Ziqian Bing, Tingting Wang, Yue Zhao Microorganisms.2026; 14(2): 471. CrossRef
Sex-specific dynamics of MASLD reveal early hepatic and extrahepatic metabolic deterioration in females despite long-term protection Maria Repollés-de-Dalmau, Anna Marsal-Beltran, Catalina Núñez-Roa, Joan Vendrell, Victòria Ceperuelo-Mallafré, Sonia Fernández-Veledo Biology of Sex Differences.2026;[Epub] CrossRef
Sex-specific cardiometabolic phenotypes in MASLD: 3PM-centric stratification and trajectory mapping for proactive risk assessment Carlos José Pirola, Luis Diambra, Tomas Fernández Gianotti, Silvia Sookoian EPMA Journal.2026; 17(2): 387. CrossRef
Dysregulation of the Gut-Adipose Tissue-Liver Axis: a Possible Mechanism Behind the Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Susanna Longo, Tommaso Giovanni Rinaldi, Jose Manuel Fernández-Real, Massimo Federici Current Diabetes Reports.2026;[Epub] CrossRef
Correspondence to letter to the editor on “Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease” Eiji Kakazu, Masaaki Mino, Tatsuya Kanto Clinical and Molecular Hepatology.2026; 32(2): e235. CrossRef
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women Ilaria Milani, Marianna Chinucci, Frida Leonetti, Danila Capoccia Biomedicines.2025; 13(4): 855. CrossRef
Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease Sheng Lyu, Jiani Yang, Xin Xin, Qinmei Sun, Beiyu Cai, Xin Wang, Ziming An, Jian Sun, Yiyang Hu, Lei Shi, Qin Feng, Xiaojun Gou BMC Gastroenterology.2025;[Epub] CrossRef
Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang Gut and Liver.2025; 19(4): 479. CrossRef
Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease Bryan Adrian Priego-Parra, Berenice M Román-Calleja, Rocio Gallego-Duran, Jordi Gracia-Sancho, Jose Antonio Velarde Ruiz-Velasco, Jose Maria Remes-Troche World Journal of Hepatology.2025;[Epub] CrossRef
Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery Stavros P. Papadakos, Chara Georgiadou, Eva Kassi, Rallia-Iliana Velliou, Antonios Chatzigeorgiou Expert Opinion on Drug Discovery.2025; 20(12): 1683. CrossRef
Identification of potential biomarkers for Polygonum multiflorum–induced liver injury in a clinical cohort: integrating machine learning of metabolomics with transcriptomic profiling Chao Lei, Meng Qiao, Chaoren Tan, Erjun Gao, Wenliang Lv, Yanming Xie, Zhifei Wang Journal of Ethnopharmacology.2026; 366: 121618. CrossRef
Cirrhotic refractory ascites: Pathogenesis, current therapeutic strategies, and future directions Linxin Zhou, Jianhui Lin Hepatobiliary Communications.2026; 1(1): 100004. CrossRef
Correspondence to editorial on: “Gut microbiome and metabolome signatures in liver cirrhosis-related complications” Satya Priya Sharma, Ki Tae Suk Clinical and Molecular Hepatology.2025; 31(1): e74. CrossRef
The crosstalk between gut microbiota and microbiota-derived metabolites in hepatocellular carcinoma Sang Jun Yoon, Seul Ki Han, Tae Suk Kim, Ki Tae Suk, Dae Hee Choi, Young Don Kim, Moon Young Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim Critical Reviews in Microbiology.2025; 51(6): 1315. CrossRef
Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang Gut and Liver.2025; 19(4): 479. CrossRef
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with a prevalence that is increasing in parallel with the global rise in obesity and type 2 diabetes mellitus. The pathogenesis of NAFLD is complex and multifactorial, involving environmental, genetic and metabolic factors. The role of the diet and the gut microbiome is gaining interest as a significant factor in NAFLD pathogenesis. Dietary factors induce alterations in the composition of the gut microbiome (dysbiosis), commonly reflected by a reduction of the beneficial species and an increase in pathogenic microbiota. Due to the close relationship between the gut and liver, altering the gut microbiome can affect liver functions; promoting hepatic steatosis and inflammation. This review summarises the current evidence supporting an association between NAFLD and the gut microbiome and dietary factors. The review also explores potential underlying mechanisms underpinning these associations and whether manipulation of the gut microbiome is a potential therapeutic strategy to prevent or treat NAFLD.
Citations
Citations to this article as recorded by
A Review of the Gut Microbiome and Its Role in Non-alcoholic Fatty Liver Disease Fahad Alfhaid Advances in Human Biology.2026; 16(1): 11. CrossRef
Low Serum sRAGE and MASLD Are Associated and Share a Similar Gut Microbiota Profile: A Prospective and Cross‐Sectional Analysis Laura Sol Grinshpan, Dana Ivancovsky‐Wajcman, Oren Tirosh, Michal Verman, Naomi Fliss‐Isakov, Muriel Webb, Oren Shibolet, Maya Ofek‐Lalzar, Revital Kariv, Shira Zelber‐Sagi Liver International.2026;[Epub] CrossRef
10-hydroxy-2(E)-decenoic acid attenuates metabolic dysfunction–associated steatotic liver disease via modulation of the gut microbiota–bile acid–FXR axis Xinyu Yu, Meifei Zhu, Kangli Wang, Bin Yuan, Yuanyuan Lu, Shanshan Li, Fuliang Hu Food Bioscience.2026; 78: 108532. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa Mohamed El-Kassas, C. Wendy Spearman, Manal El-Sayed, Zobair M. Younossi Clinics in Liver Disease.2026; 30(2): 513. CrossRef
Gut-Derived Hippuric Acid Alleviates Hepatic Lipid Metabolism via UGDH/FOXK1/CD36 Axis in Obese Mice Shuai Chen, Jiaming Xue, Yuancheng Shao, Hanyang Liu, Fangmin Zhou, Xihan Gu, Gang Zhou, Tianhan Xu, Dongmei Wang, Liming Tang Drug Design, Development and Therapy.2026; Volume 20: 1. CrossRef
Supragingival
Actinomyces naeslundii
aggravates metabolic dysfunction-associated fatty liver disease via the oral–gut axis
Ye Tu, Zhanyi Chen, Meiling Jing, Wenduo Tan, Danni Huang, Jin Xu, Min Wang, Hao Li, Yueyi Yang, Xiaoyu Liu, Xuchen Hu, Yihuai Pan, Chenguang Niu, Zhengwei Huang Journal of Oral Microbiology.2026;[Epub] CrossRef
From Bench to Bedside: Multifunctional Nanoplatforms in the Fight Against Non-alcoholic Fatty Liver Disease Yu Zhao, Luting Wang, Shengrui Zhu, Rui Feng, Wei Zhang International Journal of Nanomedicine.2026; Volume 21: 1. CrossRef
Steatotic liver disease in people with human immunodeficiency virus: A narrative review of metabolic steatotic liver disorders Nicolás Jesús Garrido, Miguel Suárez, Jorge Mateo World Journal of Hepatology.2026;[Epub] CrossRef
Recent advances in hepatoprotective polysaccharides from medicinal fungi: A decade-long review Wei Gao, Siqi Gao, Peng Xiao, Weihao Chen, Yong Chen, Jing Li, Jianjun Wu, Yu He Chinese Herbal Medicines.2026;[Epub] CrossRef
Multistrain Probiotics Alleviate Diarrhea by Modulating Microbiome-Derived Metabolites and Serotonin Pathway Jin-Ju Jeong, Yoo-Jeong Jin, Raja Ganesan, Hee Jin Park, Byeong Hyun Min, Min Kyo Jeong, Sang Jun Yoon, Mi Ran Choi, Satya Priya Sharma, You Jin Jang, Uigi Min, Jong-Hyun Lim, Kyeong Min Na, Jieun Choi, Sang Hak Han, Young Lim Ham, Do Yup Lee, Byung-Yong Probiotics and Antimicrobial Proteins.2025; 17(5): 2894. CrossRef
The causal relationship of cigarette smoking to metabolic disease risk and the possible mediating role of gut microbiota Jingda Zhang, Lin Hou, Shanxiang Lei, Yan Li, Guogang Xu Ecotoxicology and Environmental Safety.2025; 290: 117522. CrossRef
SMALL INTESTINAL BACTERIAL OVERGROWTH IN THE INTESTINE AND MICROBIOME ALTERATIONS AS A RISK FACTOR FOR LIPID METABOLISM DISORDERS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE Kh. B. Kvit, N. V. Kharchenko Art of Medicine.2025; : 38. CrossRef
Exploration of Early Diagnostic Biomarkers for Intestinal Barrier Dysfunction in Non-Alcoholic Fatty Liver Disease 庄巍 李 Advances in Clinical Medicine.2025; 15(02): 315. CrossRef
Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease Sang Yoon Lee, Su-Been Lee, Goo-Hyun Kwon, Seol Hee Song, Jeong Ha Park, Min Ju Kim, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Satya Priya Sharma, Ki Tae Journal of Microbiology.2025; 63(2): e2411002. CrossRef
Gut microbiome alterations in immune thrombocytopenia: a systematic review of current evidence Alireza Khiabani, Roohollah Mirzaee Khalilabadi, Hajar Mardani Valandani, Zahra Khoshnegah, Alireza Khanahmad, Hojat Shahraki, Najmeh Nezamabadipour, Alireza Farsinejad, Mehran Rahimlou Frontiers in Medicine.2025;[Epub] CrossRef
The crosstalk between gut microbiota and microbiota-derived metabolites in hepatocellular carcinoma Sang Jun Yoon, Seul Ki Han, Tae Suk Kim, Ki Tae Suk, Dae Hee Choi, Young Don Kim, Moon Young Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim Critical Reviews in Microbiology.2025; 51(6): 1315. CrossRef
The newly proposed dietary index for gut microbiota and its association with the risk of nonalcoholic fatty liver disease: the mediating role of body mass index Shengnan Meng, Luonan Li, Shijie Yin, Yuxuan Zhao, Yaning Liu, Yuxi Zhang, Xiaolin Zhang, Fengxue Yu Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Gut microbiota and metabolomics in metabolic dysfunction-associated fatty liver disease: interaction, mechanism, and therapeutic value Luyu Wang, Hongtao Wang, Jian Wu, Changyi Ji, Ying Wang, Mengmeng Gu, Miaomiao Li, Hongwei Yang Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
Phocaeicola dorei
ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
Jieun Choi, Ye Rin Choi, Min Kyo Jeong, Hyun Ho Song, Jeong Seok Yu, Seol Hui Song, Jeong Ha Park, Min Ju Kim, Hyunjoon Park, Young Lim Ham, Sang Hak Han, Dong Joon Kim, Do Yup Lee, Ki Tae Suk Gut Microbes.2025;[Epub] CrossRef
Fibroblast growth factor receptor inhibitors ameliorate metabolic dysfunction-associated steatohepatitis by modulating the glycine-glutathione-gut microbiota axis Hailong Li, Xiaoman Ye, Yayue Hu, Yingjun Wang, Yuting Ding, Ying Yang, Ruiqi Mao, Xi Wu, Huixuan Dong, Kaijun Qiu, Xiaohe Li, Honggang Zhou, Guang Yang, Fubao Zhang, Cheng Yang Free Radical Biology and Medicine.2025; 240: 410. CrossRef
Visiting MASLD through the lens of sex, immunity, and microbial interactions Snehanjali Puhan, Smaroki Smruti Rekha, Kartika Sahu, Tanuja Mohanty, Arka Jyoti De, Ankita Das, Palok Aich Discover Medicine.2025;[Epub] CrossRef
The AhR/IL-22 axis in chronic gut inflammation: unraveling mechanisms and therapeutic prospects Huimin Kang, Zheng Chen, Baodong Wang, Zhiyun Chen Frontiers in Immunology.2025;[Epub] CrossRef
Food Minor Bioactive Compounds of Polyphenolic and Polyprenolic Nature Are Promising Agents for the Prevention and Therapy of Non-Alcoholic Fatty Liver Disease Anastasiya Balakina, Yuliya Sidorova, Nikita Petrov, Vladimir Shipelin Molecules.2025; 30(18): 3791. CrossRef
From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease Gianmario Forcina, Vittoria Frattolillo, Maria De Cesare, Assunta Floriano, Rosamaria Palma, Federica Casamassima, Mario Bartiromo, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1329. CrossRef
Ultra-processed food consumption and non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance: A systematic review Laura Sol Grinshpan, Sigal Eilat-Adar, Dana Ivancovsky-Wajcman, Revital Kariv, Michal Gillon-Keren, Shira Zelber-Sagi JHEP Reports.2024; 6(1): 100964. CrossRef
Healthy diet intervention reverses the progression of NASH through gut microbiota modulation Suraphan Panyod, Wei-Kai Wu, Meng-Yun Hu, Huai-Syuan Huang, Rou-An Chen, Yi-Hsun Chen, Ting-Chin David Shen, Chi-Tang Ho, Chun-Jen Liu, Hsiao-Li Chuang, Chi-Chang Huang, Ming-Shiang Wu, Lee-Yan Sheen, Wei-Hua Chen Microbiology Spectrum.2024;[Epub] CrossRef
The Current and Future State of Microbiome Therapeutics in Liver Disease Patricia P. Bloom, Jasmohan S. Bajaj American Journal of Gastroenterology.2024; 119(1S): S36. CrossRef
Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon Jorge Arnold, Francisco Idalsoaga, Luis Antonio Díaz, Daniel Cabrera, Francisco Barrera, Juan Pablo Arab, Marco Arrese Current Hepatology Reports.2024; 23(1): 204. CrossRef
Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation Byeong Hyun Min, Shivani Devi, Goo Hyun Kwon, Haripriya Gupta, Jin-Ju Jeong, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Hee Jin Park, Jung A Eom, Min Kyo Jeong, Ji Ye Hyun, Nattan Stalin, Tae-Sik Park, Jieun Choi, Do Yup Lee, Sang Hak H Gut Microbes.2024;[Epub] CrossRef
Food for thought: Making the case for food produced via regenerative agriculture in the battle against non-communicable chronic diseases (NCDs) Davendra Ramkumar, Aileen Marty, Japhia Ramkumar, Holly Rosencranz, Radhika Vedantham, Modan Goldman, Erin Meyer, Jasia Steinmetz, Amy Weckle, Kelly Bloedorn, Carl Rosier One Health.2024; 18: 100734. CrossRef
Gestational supplementation of Bifidobacterium, Lactobacillus, and Streptococcus thermophilus attenuates hepatic steatosis in offspring mice through promoting fatty acid β‐oxidation Hangjun Chen, Qiongmei Wu, Xingyi Chen, Xinxue Yu, Hanqing Zhao, Qiaoli Huang, Yurong Huang, Jinting Wang, Xueyi Huang, Jun Wei, Feng Wu, Xiaomin Xiao, Lijun Wang Journal of Food Science.2024; 89(5): 3064. CrossRef
Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study Nicolás Ortiz-López, Ana María Madrid, Larissa Aleman, Alejandra Zazueta, Gladys Smok, Lucía Valenzuela-Pérez, Jaime Poniachik, Caroll J. Beltrán Frontiers in Medicine.2024;[Epub] CrossRef
Developmental Programming of the Fetal Immune System by Maternal Western-Style Diet: Mechanisms and Implications for Disease Pathways in the Offspring Benjamin N. Nelson, Jacob E. Friedman International Journal of Molecular Sciences.2024; 25(11): 5951. CrossRef
Quantification of gut microbiome metabolites using chemical isotope derivatization strategy combined with LC-MS/MS: Application in neonatal hypoxic-ischemic encephalopathy rat model Fangbo Xia, Peng Cui, Ling Liu, Junhe Chen, Qiqi Zhou, Qian Wang, Hongwei Zhou Journal of Pharmaceutical and Biomedical Analysis.2024; 248: 116312. CrossRef
An examination of global research trends for exploring the associations between the gut microbiota and nonalcoholic fatty liver disease through bibliometric and visualization analysis Sa’ed H. Zyoud, Samer O. Alalalmeh, Omar E. Hegazi, Muna Shakhshir, Faris Abushamma, Samah W. Al-Jabi Gut Pathogens.2024;[Epub] CrossRef
Gut Dysbiosis Shaped by Cocoa Butter-Based Sucrose-Free HFD Leads to Steatohepatitis, and Insulin Resistance in Mice Shihab Kochumon, Md. Zubbair Malik, Sardar Sindhu, Hossein Arefanian, Texy Jacob, Fatemah Bahman, Rasheeba Nizam, Amal Hasan, Reeby Thomas, Fatema Al-Rashed, Steve Shenouda, Ajit Wilson, Shaima Albeloushi, Nourah Almansour, Ghadeer Alhamar, Ashraf Al Madh Nutrients.2024; 16(12): 1929. CrossRef
Ginger essential oil prevents NASH progression by blocking the NLRP3 inflammasome and remodeling the gut microbiota-LPS-TLR4 pathway in mice Suraphan Panyod, Wei-Kai Wu, Ya-Chi Hsieh, Yea-Jing Tseng, Sin-Yi Peng, Rou-An Chen, Huai-Syuan Huang, Yi-Hsun Chen, Ting-Chin David Shen, Chi-Tang Ho, Chun-Jen Liu, Hsiao-Li Chuang, Chi-Chang Huang, Ming-Shiang Wu, Lee-Yan Sheen Nutrition & Diabetes.2024;[Epub] CrossRef
Altered gut microbial profile accompanied by abnormal short chain fatty acid metabolism exacerbates nonalcoholic fatty liver disease progression Chao Yang, Jiale Wu, Ligang Yang, Qiaosheng Hu, Lihua Li, Yafang Yang, Jing Hu, Da Pan, Qing Zhao Scientific Reports.2024;[Epub] CrossRef
Regulation of endotoxemia through the gut microbiota: The role of the Mediterranean diet and its components Jing Kong, Juan Yang, Cong He, Bingduo Zhou, Shengquan Fang, Manisha Salinas, Arya B. Mohabbat, Brent A. Bauer, Xiaosu Wang APMIS.2024; 132(12): 948. CrossRef
Insights of gut-liver axis in hepatic diseases: Mechanisms, clinical implications, and therapeutic potentials Naveen Jeyaraman, Madhan Jeyaraman, Tejaswin Mariappan, Sathish Muthu, Swaminathan Ramasubramanian, Shilpa Sharma, Gabriel Silva Santos, Lucas Furtado da Fonseca, José Fábio Lana World Journal of Gastrointestinal Pharmacology and Therapeutics.2024;[Epub] CrossRef
Stage dependent microbial dynamics in hepatocellular carcinoma and adjacent normal liver tissues Hee Eun Jo, Sophallika Khom, Sumi Lee, Su Hyeon Cho, Shin Young Park, Ga Ram You, Hyosin Kim, Nah Ihm Kim, Jae-Ho Jeong, Jae Hyun Yoon, Misun Yun Scientific Reports.2024;[Epub] CrossRef
Convergence of Alcohol Consumption and Dietary Quality in US Adults Who Currently Drink Alcohol: An Analysis of Two Core Risk Factors of Liver Disease Peng-Sheng Ting, Wei-Ting Lin, Suthat Liangpunsakul, Madeline Novack, Chiung-Kuei Huang, Hui-Yi Lin, Tung-Sung Tseng, Po-Hung Chen Nutrients.2024; 16(22): 3866. CrossRef
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, Ramón Bataller, Marco Arrese Nature Reviews Gastroenterology & Hepatology.2023; 20(12): 764. CrossRef
Elevated serum levels of diamine oxidase, D-lactate and lipopolysaccharides are associated with metabolic-associated fatty liver disease Ruike Zhang, Ya-nan Chen, Jixia Zhang, Jing Liu European Journal of Gastroenterology & Hepatology.2023; 35(1): 94. CrossRef
Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol Ming Yang, Xiaoqiang Qi, Nan Li, Jussuf T. Kaifi, Shiyou Chen, Andrew A. Wheeler, Eric T. Kimchi, Aaron C. Ericsson, R. Scott Rector, Kevin F. Staveley-O’Carroll, Guangfu Li Nature Communications.2023;[Epub] CrossRef
The identification of metabolites from gut microbiota in NAFLD via network pharmacology Ki-Kwang Oh, Haripriya Gupta, Byeong Hyun Min, Raja Ganesan, Satya Priya Sharma, Sung Min Won, Jin Ju Jeong, Su Been Lee, Min Gi Cha, Goo Hyun Kwon, Min Kyo Jeong, Ji Ye Hyun, Jung A Eom, Hee Jin Park, Sang Jun Yoon, Mi Ran Choi, Dong Joon Kim, Ki Tae Suk Scientific Reports.2023;[Epub] CrossRef
Comparison between obese and non-obese nonalcoholic fatty liver disease Wah-Kheong Chan Clinical and Molecular Hepatology.2023; 29(Suppl): S58. CrossRef
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef
MicroRNA‐29a Compromises Hepatic Adiposis and Gut Dysbiosis in High Fat Diet‐Fed Mice via Downregulating Inflammation Ya‐Ling Yang, Ying‐Hsien Huang, Feng‐Sheng Wang, Ming‐Chao Tsai, Chien‐Hung Chen, Wei‐Shiung Lian Molecular Nutrition & Food Research.2023;[Epub] CrossRef
Valuable effects of lactobacillus and citicoline on steatohepatitis: role of Nrf2/HO-1 and gut microbiota Ahmed M. El-Baz, Amira M. El-Ganiny, Doaa Hellal, Hala M. Anwer, Hend A. Abd El-Aziz, Ibrahim E. Tharwat, Mohamed A. El-Adawy, Shehab El-Din M. Helal, Menna Tallah A. Mohamed, Tassnim M. Azb, Hanya M. Elshafaey, AbdulRahman A. Shalata, Sahar M. Elmeligi, AMB Express.2023;[Epub] CrossRef
Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients Christoph Roderburg, Sarah Krieg, Andreas Krieg, Sascha Vaghiri, Raphael Mohr, Marcel Konrad, Mark Luedde, Tom Luedde, Karel Kostev, Sven H. Loosen Clinical Research in Cardiology.2023; 112(10): 1446. CrossRef
Blueberry and Blackberry Anthocyanins Ameliorate Metabolic Syndrome by Modulating Gut Microbiota and Short-Chain Fatty Acids Metabolism in High-Fat Diet-Fed C57BL/6J Mice Lanlan Du, Han Lü, Yan Chen, Xiaohua Yu, Tunyu Jian, Huifang Zhao, Wenlong Wu, Xiaoqin Ding, Jian Chen, Weilin Li Journal of Agricultural and Food Chemistry.2023; 71(40): 14649. CrossRef
The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status Josip Stojic, Michał Kukla, Ivica Grgurevic Diagnostics.2023; 13(18): 2960. CrossRef
Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease” Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 1050. CrossRef
A High-Fat Diet Increases the Characteristics of Gut Microbial Composition and the Intestinal Damage Associated with Non-Alcoholic Fatty Liver Disease Xiaoyang Zhu, Jiajia Cai, Yifu Wang, Xinyu Liu, Xiaolei Chen, Haifei Wang, Zhengchang Wu, Wenbin Bao, Hairui Fan, Shenglong Wu International Journal of Molecular Sciences.2023; 24(23): 16733. CrossRef
Preventive Effects of Apple Polyphenol Extract on High-Fat-Diet-Induced Hepatic Steatosis Are Related to the Regulation of Hepatic Lipid Metabolism, Autophagy, and Gut Microbiota in Aged Mice Yan Yin, Yisha Xie, Zhengli Wu, Qingfan Qian, Hao Yang, Shilan Li, Xinli Li Journal of Agricultural and Food Chemistry.2023; 71(50): 20011. CrossRef
Design and Usability Evaluation of a Self-Care Application for Non-Alcoholic Fatty Liver Disease Patients with Overweight: Approach Leveraging Behavior Change Techniques (Preprint) Azam Kheirdoust, Mohammad Reza Mazaheri Habibi, Mohsen Nematy, Ali Jafarzadeh Esfahani, Kosar Ghaddaripour, Saeid Eslami JMIR Human Factors.2023;[Epub] CrossRef
The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases Lingxuan An, Ulrich Wirth, Dominik Koch, Malte Schirren, Moritz Drefs, Dionysios Koliogiannis, Hanno Nieß, Joachim Andrassy, Markus Guba, Alexandr V. Bazhin, Jens Werner, Florian Kühn Journal of Gastrointestinal Surgery.2022; 26(3): 671. CrossRef
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease Alessandro Mantovani, Christopher D. Byrne, Giovanni Benfari, Stefano Bonapace, Tracey G. Simon, Giovanni Targher Journal of the American College of Cardiology.2022; 79(2): 180. CrossRef
Oxidative Stress in Non-Alcoholic Fatty Liver Disease Carlo Smirne, Eleonora Croce, Davide Di Benedetto, Vincenzo Cantaluppi, Cristoforo Comi, Pier Paolo Sainaghi, Rosalba Minisini, Elena Grossini, Mario Pirisi Livers.2022; 2(1): 30. CrossRef
Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study Byoungduck Han, Gyu Bae Lee, Sun Young Yim, Kyung-Hwan Cho, Koh Eun Shin, Jung-Hwan Kim, Yong-Gyu Park, Kyung-Do Han, Yang-Hyun Kim Diagnostics.2022; 12(3): 663. CrossRef
Pterostilbene and Its Derivative 3′-Hydroxypterostilbene Ameliorated Nonalcoholic Fatty Liver Disease Through Synergistic Modulation of the Gut Microbiota and SIRT1/AMPK Signaling Pathway Hui-Yun Tsai, Yu-Yuan Shih, Yao-Tsung Yeh, Cheng-Hsieh Huang, Chorng-An Liao, Chun-Yi Hu, Kalyanam Nagabhushanam, Chi-Tang Ho, Yu-Kuo Chen Journal of Agricultural and Food Chemistry.2022; 70(16): 4966. CrossRef
The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats Yufan Dai, Wenyu Zhu, Jiaxuan Zhou, Tao Shen Brazilian Journal of Medical and Biological Research.2022;[Epub] CrossRef
Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Mira Kang, Eliseo Guallar, Yun Soo Hong, Kyung Hyun Lee, Jiyeon Park, Juhee Cho, Geum‐Youn Gwak Hepatology.2022; 76(6): 1746. CrossRef
The Role of Rumen Microbiota and Its Metabolites in Subacute Ruminal Acidosis (SARA)-Induced Inflammatory Diseases of Ruminants Yunhe Fu, Yuhong He, Kaihe Xiang, Caijun Zhao, Zhaoqi He, Min Qiu, Xiaoyu Hu, Naisheng Zhang Microorganisms.2022; 10(8): 1495. CrossRef
Oral administration of branched-chain amino acids ameliorates high-fat diet-induced metabolic-associated fatty liver disease via gut microbiota-associated mechanisms Ranran Zhang, Hongna Mu, Ziyun Li, Jie Zeng, Qi Zhou, Hongxia Li, Siming Wang, Xianghui Li, Xianghui Zhao, Liang Sun, Wenxiang Chen, Jun Dong, Ruiyue Yang Frontiers in Microbiology.2022;[Epub] CrossRef
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim Hepatology Research.2022; 52(12): 975. CrossRef
The gut microbiota–bile acid axis: A potential therapeutic target for liver fibrosis Yu-Lin Zhang, Zhen-Jiao Li, Hong-Zhong Gou, Xiao-Jing Song, Lei Zhang Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef
The role of the intestinal permeability in the progression of nonalcoholic fatty liver disease in obese children Yu.M. Stepanov, N.Yu. Zavhorodnia, N.O. Zhyhyr GASTROENTEROLOGY.2022; 56(1): 20. CrossRef
The Gut-Liver Axis in Cholestatic Liver Diseases Andreas Blesl, Vanessa Stadlbauer Nutrients.2021; 13(3): 1018. CrossRef
Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease Joo Hyun Oh, Je Hee Lee, Min Seok Cho, Hyeree Kim, Jongsik Chun, Joon Hyeok Lee, Yeup Yoon, Wonseok Kang Nutrients.2021; 13(3): 1013. CrossRef
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach Giovanni Targher, Herbert Tilg, Christopher D Byrne The Lancet Gastroenterology & Hepatology.2021; 6(7): 578. CrossRef
CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload Riina Harjumäki, Chris S. Pridgeon, Magnus Ingelman-Sundberg International Journal of Molecular Sciences.2021; 22(15): 8221. CrossRef
Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases Satya Priya Sharma, Ki Tae Suk, Dong Joon Kim World Journal of Gastroenterology.2021; 27(37): 6161. CrossRef
Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa C Wendy Spearman, Mary Afihene, Omolade Betiku, Bilal Bobat, Lina Cunha, Chris Kassianides, Leolin Katsidzira, Hailemichael D Mekonnen, Ponsiano Ocama, Olusegun Ojo, Imran Paruk, Christian Tzeuton, Mark W Sonderup The Lancet Gastroenterology & Hepatology.2021; 6(12): 1036. CrossRef
Diet-Regulating Microbiota and Host Immune System in Liver Disease Jung A Eom, Goo Hyun Kwon, Na Yeon Kim, Eun Ju Park, Sung Min Won, Jin Ju Jeong, Ganesan Raja, Haripriya Gupta, Yoseph Asmelash Gebru, Satyapriya Sharma, Ye Rin Choi, Hyeong Seop Kim, Sang Jun Yoon, Ji Ye Hyun, Min Kyo Jeong, Hee Jin Park, Byeong Hyun Min International Journal of Molecular Sciences.2021; 22(12): 6326. CrossRef
Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease Li-Hong He, Dun-Han Yao, Ling-Yun Wang, Lei Zhang, Xue-Li Bai Frontiers in Microbiology.2021;[Epub] CrossRef
INSULIN RESISTANCE AS AN INDICATOR OF DIFFERENTIATION FOR THE FORMATION OF RISK GROUPS FOR NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITHOUT TYPE 2 DIABETES MELLITUS, AS A PART OF ONTOLOGICAL MODEL OF NON-ALCOHOLIC FATTY LIVER DISEASE Natalia O. Nosko, Viacheslav V. Kharchenko Wiadomości Lekarskie.2021; 74(10): 2593. CrossRef
Dual role of neutrophils in modulating liver injury and fibrosis during development and resolution of diet-induced murine steatohepatitis Andrea D. Kim, Sung Eun Kim, Aleksandra Leszczynska, Benedikt Kaufmann, Agustina Reca, Dong Joon Kim, Ariel E. Feldstein Scientific Reports.2021;[Epub] CrossRef
Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection Yi Jiang, Salil Chowdhury, Bing-Hong Xu, Mohamad Aghaie Meybodi, Konstantinos Damiris, Samanthika Devalaraju, Nikolaos Pyrsopoulos World Journal of Hepatology.2021; 13(11): 1777. CrossRef
Systemic hematologic, metabolic, and inflammatory dysregulation in liver cirrhosis and hepatocellular carcinoma: diagnostic utility of novel indices in an Egyptian cohort Dalia E. Sherief, Hadeer Hamdy Shehata, Nahla Nosair, Amira A. A. Othman, Mohamed W. Saleh, Emad Sadaka, Rasha Elgamal BMC Gastroenterology.2026;[Epub] CrossRef
Integrative transcriptomic analysis reveals miR-26a-5p downregulation and a potential predictive gene signature for the progression of metabolic liver disease Andrei Sorop, Alina-Veronica Ghionescu, Diana Larisa Ancuța, Maria-Gabriela Croitoru, Cristin Coman, Daniela Lixandru, Simona Olimpia Dima Frontiers in Cell and Developmental Biology.2026;[Epub] CrossRef
Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma Dong Hyun Kim, Eun Min Kim, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Gi Hong Choi, Sang Hoon Ahn, Hye Won Lee, Do Young Kim Cancers.2025; 17(4): 566. CrossRef
Biosocial Determinants of Health Among Patients with Chronic Liver Disease and Liver Cancer Tagari Samanta, Jun Hyoung Park, Benny Abraham Kaipparettu Cancers.2025; 17(5): 844. CrossRef
Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an analysis from the GBD 2021 and forecast to 2050 Jianing Shi, Xuan Wu, Jiali Yu, Qingli Zhou Frontiers in Nutrition.2025;[Epub] CrossRef
Large duct primary sclerosing cholangitis with or without inflammatory bowel disease in Saudi patients Hamdan S. AlGhamdi, Nawaf M. AlYahya, Ibrahim M. Bahabri, Majed A. Al Ashaikh, Abdulrahman K. Habib, Abdulaziz A. AlAhmary, Nuha Al Ajlan, Abdulrahman I. AlAbdulgader, Abduljaleel M. Alalwan, Faisal M. Sanai Saudi Journal of Gastroenterology.2025; 31(6): 356. CrossRef
Non-Viral Hepatocellular Carcinoma with Normal Alpha-Fetoprotein but Elevated CA19-9 in an Older Patient with Obesity: A Case Report Seung Hun Lee, Mi Soo Kim, Jeong Gyu Lee Korean Journal of Geriatrics & Gerontology.2025; 26(3): 147. CrossRef
Nanoquercetin and Extracellular Vesicles as Potential Anticancer Therapeutics in Hepatocellular Carcinoma Alok Raghav, Goo Bo Jeong Cells.2024; 13(7): 638. CrossRef
Hepatitis B-related hepatocellular carcinoma: classification and prognostic model based on programmed cell death genes Jinyue Tian, Jiao Meng, Zhenkun Yang, Li Song, Xinyi Jiang, Jian Zou Frontiers in Immunology.2024;[Epub] CrossRef
Burden of uterine cancer in China from 1990 to 2021 and 15-year projection: a systematic analysis and comparison with global levels Zhan Lin, Mei Gan, Xiangping Wang, Zhonghua Su Reproductive Health.2024;[Epub] CrossRef
Recent Trends in Liver Cancer: Epidemiology, Risk Factors, and Diagnostic Techniques Shivani R Kale, Geeta Karande, Anand Gudur, Aishwarya Garud, Monika S Patil, Satish Patil Cureus.2024;[Epub] CrossRef
Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy” Seren M. Gedallovich, Paul Y. Kwo Clinical and Molecular Hepatology.2024; 30(4): 1050. CrossRef
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(1): 99. CrossRef
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith Clinical and Molecular Hepatology.2023; 29(2): 433. CrossRef
Occurrence of Liver Cancer in People without Traditional Risk Factors Junho Choi, Joohyun Park, Jae Kwang Lee, Kyunghee Cho Korean Journal of Clinical Geriatrics.2023; 24(1): 41. CrossRef
The Role of the Gut Microbiome and the Hepatic Axis in the Pathogenesis of Metabolic Syndrome and Therapeutics K. P. Divya, Parneet Hari, Navjot Kanwar, Navita Aggarwal, Preeti Singh Dhoat, Lu Liu, Abhinav Kanwal, Shailendra Pratap Singh, Jiong Yu Advanced Gut & Microbiome Research.2023; 2023: 1. CrossRef
Bursatella leachii Purple Ink Secretion Concentrate Exerts Cytotoxic Properties against Human Hepatocarcinoma Cell Line (HepG2): In Vitro and In Silico Studies Zeyad I. Alehaideb, Anuradha Venkatraman, Mahadev Kokane, Syed Ali Mohamed, Saranya Rameshbabu, Rasha S. Suliman, Sahar S. Alghamdi, Hamad Al-Eidi, Bandar Alghanem, Maha-Hamadien Abdulla, Sabine Matou-Nasri Molecules.2022; 27(3): 826. CrossRef
The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu Frontiers in Oncology.2022;[Epub] CrossRef
Association between metabolic syndrome, C-reactive protein, and the risk of primary liver cancer: a large prospective study Mengmeng Song, Tong Liu, Hai Liu, Qi Zhang, Qingsong Zhang, Yiming Wang, Xiangming Ma, Liying Cao, Hanping Shi BMC Cancer.2022;[Epub] CrossRef
Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease Joo Hyun Oh, Je Hee Lee, Min Seok Cho, Hyeree Kim, Jongsik Chun, Joon Hyeok Lee, Yeup Yoon, Wonseok Kang Nutrients.2021; 13(3): 1013. CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim Cancers.2021; 13(14): 3424. CrossRef
Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro Translational Oncology.2021; 14(9): 101158. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Na Young Lee, Min Jea Shin, Gi Soo Youn, Sang Jun Yoon, Ye Rin Choi, Hyeong Seop Kim, Haripriya Gupta, Sang Hak Han, Byoung Kook Kim, Do Yup Lee, Tae Sik Park, Hotaik Sung, Byung Yong Kim, Ki Tae Suk
Clin Mol Hepatol 2021;27(1):110-124. Published online December 3, 2020
Background/Aims Nonalcoholic fatty liver disease (NAFLD) is closely related to gut-microbiome. There is a paucity of research on which strains of gut microbiota affect the progression of NAFLD. This study explored the NAFLD-associated microbiome in humans and the role of Lactobacillus in the progression of NAFLD in mice.
Methods The gut microbiome was analyzed via next-generation sequencing in healthy people (n=37) and NAFLD patients with elevated liver enzymes (n=57). Six-week-old male C57BL/6J mice were separated into six groups (n=10 per group; normal, Western, and four Western diet + strains [109 colony-forming units/g for 8 weeks; L. acidophilus, L. fermentum, L. paracasei, and L. plantarum]). Liver/body weight ratio, liver pathology, serum analysis, and metagenomics in the mice were examined.
Results Compared to healthy subjects (1.6±4.3), NAFLD patients showed an elevated Firmicutes/Bacteroidetes ratio (25.0±29.0) and a reduced composition of Akkermansia and L. murinus (P<0.05). In the animal experiment, L. acidophilus group was associated with a significant reduction in liver/body weight ratio (5.5±0.4) compared to the Western group (6.2±0.6) (P<0.05). L. acidophilus (41.0±8.6), L. fermentum (44.3±12.6), and L. plantarum (39.0±7.6) groups showed decreased cholesterol levels compared to the Western group (85.7±8.6) (P<0.05). In comparison of steatosis, L. acidophilus (1.9±0.6), L. plantarum (2.4±0.7), and L. paracasei (2.0±0.9) groups showed significant improvement of steatosis compared to the Western group (2.6±0.5) (P<0.05).
Conclusions Ingestion of Lactobacillus, such as L. acidophilus, L. fermentum, and L. plantarum, ameliorates the progression of nonalcoholic steatosis by lowering cholesterol. The use of Lactobacillus can be considered as a useful strategy for the treatment of NAFLD.
Citations
Citations to this article as recorded by
Black Sesame Pigment Ameliorates Non-Alcoholic Fatty Liver Disease via Modulation of the Gut–Liver Axis and HIF-1 Signaling Pathway Qian Huang, Zhuowen Liang, Qingpeng Li, Ke Wang, Shuang Zhu, Wei Xiao, Lin Zhou Antioxidants.2026; 15(2): 177. CrossRef
Alteration in tongue coating microbiota across different stages of hepatitis B virus-related chronic liver disease Umar Pervaiz, Fuxia Wu, Pervaiz Nabeel, Rui Zhao, Zhengbin Zhao, Yibao Zhang, Peng Xia, Pengfei Ji, Xinyi Yuan, Xiaohui Hu, Zhao Guo, Kun Xie, Fang Wang, Degui Wang Journal of Oral Microbiology.2026;[Epub] CrossRef
Probiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights Supriyo Ghosh, Amlan Jyoti Ghosh, Manab Deb Adhikari, Bipransh Kumar Tiwary, Tilak Saha Journal of Diabetes & Metabolic Disorders.2026;[Epub] CrossRef
Advances in Cholesterol Regulation by
Lactobacillus
: Technical Approaches, Mechanisms of Action, and Potential for Clinical Translation
Jingjing Wang, Yuxin Wang, Yangying Sun, Xiaojiao Zheng, Xiaoqun Zeng, Zhen Wu, Daodong Pan, Maolin Tu Food Reviews International.2026; 42(5): 3760. CrossRef
Lactobacillus murinus Alleviates High Fructose‐Induced MASLD by Boosting Arginine Production Xinglin Mo, Guilin Zhao, Lanlan Liu, Lan Zhen, Qing Huang, Yue Wang, Xiaopan Yang, Linfei Huang, Luming Wan, Congwen Wei, Ruzhou Zhao, Jie Hu, Yong Li, Jing Yuan, Chenke Ma, Feixiang Wu Food Science & Nutrition.2026;[Epub] CrossRef
Lacticaseibacillus rhamnosus B6 alleviates metabolic dysfunction-associated fatty liver disease by suppressing intestinal LPS synthesis and regulating lipid metabolism Danqi Wang, Jin Han, Xiaohua Wang, Jing Wang, Chunping You, Zhengjun Wu Frontiers in Endocrinology.2026;[Epub] CrossRef
Long-term systemic effects of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/MAFLD) in children: a systematic review of persistence and progression into adulthood Beatriz Rey-Garcia, Maria Teresa Reyes-Chacon, Eduardo Rosas-Blum, Marie Leiner Annals of Hepatology.2026; 31(1): 102197. CrossRef
Hepatoprotective effect of administering a probiotic strain (Lactobacillus acidophilus) to mice when consuming sucrose Marco Soria-Mamani, Oscar Gustavo Huaman Gutierrez Nutrire.2026;[Epub] CrossRef
Pathogenesis of fatty liver haemorrhagic syndrome in laying hens and advances in nutritional intervention through feed additives Lanlan Li, Jie Gao, Xin Wang, Yujiao Lai, Zhengfan Zhang, Shuangshuang Guo, Binying Ding World's Poultry Science Journal.2026; : 1. CrossRef
MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues Suki Ha, Xiang Zhang, Lanjuan Li, Jun Yu Science Bulletin.2026; 71(11): 2916. CrossRef
Diabetes and Obesity as Catalysts in MASH Progression: Mechanisms and Emerging Therapies Bhumika Munda, Chimila Bhutia, Deepti, Manisha Khatri Letters in Applied NanoBioScience.2026;[Epub] CrossRef
Obesity, type 2 diabetes, and the gut microbiome: A case-control investigation of L. acidophilus, L. rhamnosus, and B. bifidum Niloofar Sadooghi, Amir Mohammad Salimi Sharif, Soheil Rahmani Fard, Somayeh Soleymanzadeh Moghadam, Sara Minaeian Endocrine and Metabolic Science.2026; 21: 100308. CrossRef
Lactobacillaceae in Acute and Chronic Liver Diseases: From Microbiota Modulation to Therapeutic Potential Xulan Zhang, Yi Xia, Feng Ji Probiotics and Antimicrobial Proteins.2026;[Epub] CrossRef
Probiotic Bifidobacterium bifidum BGN4 supplementation modulates gut microbiome composition and reduces circulating zonulin, TNFα, and insulin in adults with excess adiposity: a randomized, double-blind, placebo-controlled trial Ju-Won Choi, Hyeyoon Kim, Sung-Hee Ham, Ye-Jin Han, Sung-Eun Kim, Mi-Kyung Sung Nutrition & Metabolism.2026;[Epub] CrossRef
Dietary milk polar lipids ameliorate hepatic lipid accumulation through coordinated regulation of Wnt-PPARγ signaling and remodeling of the gut microbiota Hajin Kim, Dongjun Park, Yea-ji Kwon, Jee-Young Imm Food Science of Animal Resources.2026;[Epub] CrossRef
Correspondence to editorial on “Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production” Dianji Tu, Cheng Lu, Bo Tang, Shiming Yang Clinical and Molecular Hepatology.2026; 32(3): e358. CrossRef
Роль биологически активных соединений в кисломолочных продуктах геродиетической направленности
Анна Васильевна Бегунова, Сергей Владимирович Симоненко, Елена Сергеевна Симоненко, Елена Сергеевна Семенова Food processing industry.2026; (8): 154. CrossRef
Multistrain Probiotics Alleviate Diarrhea by Modulating Microbiome-Derived Metabolites and Serotonin Pathway Jin-Ju Jeong, Yoo-Jeong Jin, Raja Ganesan, Hee Jin Park, Byeong Hyun Min, Min Kyo Jeong, Sang Jun Yoon, Mi Ran Choi, Satya Priya Sharma, You Jin Jang, Uigi Min, Jong-Hyun Lim, Kyeong Min Na, Jieun Choi, Sang Hak Han, Young Lim Ham, Do Yup Lee, Byung-Yong Probiotics and Antimicrobial Proteins.2025; 17(5): 2894. CrossRef
Comparative effects of viable Lactobacillus rhamnosus GG and its heat‐inactivated paraprobiotic in the prevention of high‐fat high‐fructose diet‐induced non‐alcoholic fatty liver disease in rats Laura Isabel Arellano‐García, Iñaki Milton‐Laskibar, J. Alfredo Martínez, Miguel Arán‐González, María P. Portillo BioFactors.2025;[Epub] CrossRef
Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction‐associated steatotic liver disease: a comprehensive review Jie‐Lun Ku, Jia‐Rou Hsu, Yung‐Tsung Li, Li‐Ling Wu Journal of Gastroenterology and Hepatology.2025; 40(1): 33. CrossRef
The Role of the Gut Microbiome in the Development and Progression of Type 2 Diabetes and Liver Disease Asha Guraka, Sreejesh Sreedharan, Ramesh Arasaradnam, Gyan Tripathi, Ali Kermanizadeh Nutrition Reviews.2025; 83(7): e2025. CrossRef
Research hotspots and trends in gut microbiota and nonalcoholic fatty liver disease: A bibliometric study Cai-Yun Huang, Zhong-Zhi Luo, Wei-Ping Huang, Li-Ping Lin, You-Ting Yao, Han-Xu Zhuang, Qiu-Yong Xu, Ya-Dong Lai World Journal of Hepatology.2025;[Epub] CrossRef
Gut microbiota: A new key of understanding for Panax notoginseng against multiple disorders and biotransformation Yueting Mo, Xiyuan He, Hao Cui, Yifan Cheng, Mingmei Zhou, Xiuming Cui, Ting Zhang Journal of Ethnopharmacology.2025; 341: 119306. CrossRef
Microbiota Co-Metabolism Alterations Precede Changes in the Host Metabolism in the Early Stages of Diet-Induced MASLD in Wistar Rats María Martín-Grau, Pilar Casanova, Laura Moreno-Morcillo, José Manuel Morales, Vannina G. Marrachelli, Daniel Monleón International Journal of Molecular Sciences.2025; 26(3): 1288. CrossRef
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo International Journal of Molecular Sciences.2025; 26(4): 1778. CrossRef
Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease Sang Yoon Lee, Su-Been Lee, Goo-Hyun Kwon, Seol Hee Song, Jeong Ha Park, Min Ju Kim, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Satya Priya Sharma, Ki Tae Journal of Microbiology.2025; 63(2): e2411002. CrossRef
JiGuCao capsule formula alleviates metabolic fatty liver disease by regulating the gut–liver axis and lipid metabolism Wenying Qi, Xu Cao, Yue Chen, Hening Chen, Ningyi Zhang, Ruijia Liu, Wei Wang, Qiyao Liu, Shihao Zheng, Size Li, Xiaoke Li, Xiaobin Zao, Yong'an Ye Phytomedicine.2025; 140: 156559. CrossRef
Benefits of inulin and fructo-oligosaccharides on high fat diet-induced type 2 diabetes mellitus by regulating the gut microbiota in mice Xiaoqin Ding, Yan Chen, Lanlan Du, Jing Li, Xiuhua Meng, Han Lv, Bei Tong, Guanting Niu, Tunyu Jian, Jian Chen The Journal of Nutritional Biochemistry.2025; 141: 109908. CrossRef
Administration of a probiotic supplement attenuates nonalcoholic fatty liver disease by reducing hepatic lipid accumulation, oxidative stress, and inflammation Pennapa CHONPATHOMPIKUNLERT, Pratoomporn YINGTHONGCHAI, Suriya TATEING, Anuwat AMATACHAYA, Sasalux KAEWBUTRA, Neungnut CHAIYAWAN, Thanyarat LEKCHAOUM, Chaivarakun CHAIPANYA, Wachirawadee MALAKUL, Jurairat KHONGRUM Bioscience of Microbiota, Food and Health.2025; 44(2): 160. CrossRef
Integrating microbial GWAS and single-cell transcriptomics reveals associations between host cell populations and the gut microbiome Jingjing Li, Yunlong Ma, Yue Cao, Gongwei Zheng, Qing Ren, Cheng Chen, Qunyan Zhu, Yijun Zhou, Yu Lu, Yaru Zhang, Chunyu Deng, Wei-Hua Chen, Jianzhong Su Nature Microbiology.2025; 10(5): 1210. CrossRef
Harnessing
lactobacillus
: a probiotic revolution in combating metabolic dysfunction-associated steatotic liver disease
Minwen Gu, Qing Hong, Jie Cui, Wenhui Li, Jian Zhang, Ye Sun, Jinchi Jiang, Yonghong Hu Critical Reviews in Food Science and Nutrition.2025; 65(33): 8516. CrossRef
Effects of Lactobacillus fermentum GKF3 on Reducing Smoking and Brain Neurotransmitter Levels: Findings From Animal and Human Studies You‐Shan Tsai, Shan Lin, Chin‐Chu Chen, Chun‐Hung Chiu, Mei‐Chin Mong, Shu‐Ling Hu, Chi‐Hao Wu Food Frontiers.2025; 6(4): 2065. CrossRef
Exploring the mechanisms of tetrahydrocurcumin in ameliorating nonalcoholic steatohepatitis based on network pharmacology and gut microbiota analysis in vivo and in vitro Keyu Chen, Jianbo Wang, Shuang Luo, Yunyun Quan, Ping Wei, Jiali Fu, Jiali Ma, Yuying Yang, Yunten Liu, Zhichong Gao Frontiers in Microbiology.2025;[Epub] CrossRef
The liver-gut axis perspective: Exploring the pathogenesis of fatty liver Zonghui Yang, Jinbao Zhang, Xiaona Liu, Honggang Chen, Haijing Duan, Qian Wang, Wenlong Zhao, Ling Jin European Journal of Pharmacology.2025; 1002: 177822. CrossRef
Optimization of microwave-assisted extraction for quercetin (prebiotic) and the effect of its symbiotic combination with Lactobacillus acidophilus (probiotic) in NAFLD induced rat model Mehwish Majeed, Waqas Ahmed, Sumera Javad, Iahtisham-Ul-Haq, Summer Rashid, Rashida Perveen, Umar Farooq, Juweria Abid, Abdul Momin Rizwan Ahmad Frontiers in Nutrition.2025;[Epub] CrossRef
The Effects of Wuniuzao Green Tea on Mice With High‐Fat Diet‐Induced Liver Steatosis Yiwei Yuan, Jiangcheng Ye, Mingxiu Gong, Yifan Zhang, Qianqian Xu, Jin Zhao Food Science & Nutrition.2025;[Epub] CrossRef
Probiotics as a therapeutic strategy for metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis Jing Lu, Xiaoxiao Dong, Ziqi Gao, Huizhen Yan, Dilireba Shataer, Liang Wang, Yanan Qin, Minwei Zhang, Jiayi Wang, Jie Cui, Shengyang Zhou Current Research in Food Science.2025; 11: 101138. CrossRef
Gastrointestinal Microbial Involvement in Gallstone Formation: A Systematic Review Sirui Wan, Kun Xia, Yunpeng Liu, Hongzhi Xu Health and Metabolism.2025; : 3. CrossRef
Cistanche tubulosa glycosides ameliorate cognitive decline in APP/PS1 mice via modulation of gut microbiota and fatty acid metabolism: insights from multi-omics and experimental validation Rui Hou, Wei Song, Yi Nan, Yiyi Gong, Jieying Liu, Jialin Liu Frontiers in Pharmacology.2025;[Epub] CrossRef
MicrobiomeKG: bridging microbiome research and host health through knowledge graphs Skye L. Goetz, Amy K. Glen, Gwênlyn Glusman Frontiers in Systems Biology.2025;[Epub] CrossRef
Changes in viable cell counts and functional properties of lactic
acid bacteria products under simulated marine shipping
conditions Se-Won Lee, Joong Sang Cho, Jeong-Muk Lim, Do-Yoeon Jang, Jun Hur, Jun Jae Jung, Byung-Taek Oh Food Science and Preservation.2025; 32(4): 603. CrossRef
Stachyose Attenuates Hepatic Cholesterol Deposition in Nonalcoholic Fatty Liver Mice via Gut Microbiota-Driven Bile Acid Profile Remodeling Yanqi Li, Ying Fan, Yashi Zhang, Aizhen Zong, Fangling Du, Tongcheng Xu Journal of Agricultural and Food Chemistry.2025; 73(41): 26130. CrossRef
Akkermansia muciniphila: a microbial guardian against oxidative stress–gut microbiota crosstalk and clinical prospects Wen-Yu Ye, Yan Cai Journal of Translational Medicine.2025;[Epub] CrossRef
The Gut Health Revolution: Herbs and Dietary Phytochemicals in Balancing Gut Microbiota for Optimal Human Health Afeefa Khan, Sageer Abass, Syed Ali Imam Nizami, Mohd Shariq, Sultan Zahiruddin, Bushra Parveen, Rabea Parveen Current Pharmaceutical Biotechnology.2025; 26(14): 2339. CrossRef
Revealing the Causal Relationship of the Gut‐Liver Axis in MASH: A Study Based on Mendelian Randomization and Multi‐Omics Dapeng Yin, Jiacheng Cheng, Huili Cao, Xiaojuan Wang, Junhua He, Yikun Zhu, Jin Li The FASEB Journal.2025;[Epub] CrossRef
Lactobacillus gasseri TF08-1 ameliorates high-fat diet induced nonalcoholic fatty liver disease and regulates gut microbiota in mice Qianyue Xu, Ningning He, Yu Tian, Zhinan Wu, Haoyu Wang, Bei Liu, Zizhen Yang, Haifeng Zhang, Qiang Luo, Yiyi Zhong, Liang Xiao, Shangyong Li, Yuanqiang Zou Journal of Applied Microbiology.2025;[Epub] CrossRef
The Dual Role of Gut Microbiota and Their Metabolites in Hepatocellular Carcinoma: A Context-Dependent Framework Shuyu Zuo, Junhui Ma, Xue Li, Zhengyang Fan, Xiao Li, Yingen Luo, Lei Su Microorganisms.2025; 14(1): 73. CrossRef
Changes in viable cell counts and functional properties of lactic
acid bacteria products under simulated marine shipping
conditions Se-Won Lee, Joong Sang Cho, Jeong-Muk Lim, Do-Yoeon Jang, Jun Hur, Jun Jae Jung, Byung-Taek Oh Food Science and Preservation.2025; 32(4): 603. CrossRef
Pien Tze Huang Protects Against Non-Alcoholic Steatohepatitis by Modulating the Gut Microbiota and Metabolites in Mice Xianyi Zeng, Xiang Zhang, Hao Su, Hongyan Gou, Harry Cheuk-Hay Lau, Xiaoxu Hu, Ziheng Huang, Yan Li, Jun Yu Engineering.2024; 35: 257. CrossRef
The Effect of Heat-Killed Lactobacillus plantarum on Oxidative Stress and Liver Damage in Rats with Bile Duct Ligation-Induced Hepatic Fibrosis Shima Kabiri-Arani, Mitra Motallebi, Maryam Akhavan Taheri, Nejat Kheiripour, Abolfazl Ardjmand, Esmat Aghadavod, Mohammad Esmaeil Shahaboddin Probiotics and Antimicrobial Proteins.2024; 16(1): 196. CrossRef
Composition of gut microbiota and non‐alcoholic fatty liver disease: A systematic review and meta‐analysis Xin Su, Shiyun Chen, Jiazi Liu, Yonghui Feng, Eerdun Han, Xiaolei Hao, Minqi Liao, Jun Cai, Shiwen Zhang, Jianxiang Niu, Shihua He, Shaofen Huang, Kenneth Lo, Fangfang Zeng Obesity Reviews.2024;[Epub] CrossRef
Polysaccharide from Panax japonicus C.A. Mey prevents non-alcoholic fatty liver disease development based on regulating liver metabolism and gut microbiota in mice Yi Wu, Wen Yin, Ping Hao, Yueru Chen, Lingyun Yu, Xingjian Yu, Yu Wu, Xiaocong Li, Wenjia Wang, Hui Zhou, Yuan Yuan, Xiaoyu Quan, Yue Yu, Bing Hu, Shouhai Chen, Zhenlei Zhou, Wenjing Sun International Journal of Biological Macromolecules.2024; 260: 129430. CrossRef
Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction Wasitha P. D. W. Thilakarathna, H. P. Vasantha Rupasinghe Molecules.2024; 29(3): 709. CrossRef
Effects of selenium nanoparticles produced by Lactobacillus acidophilus HN23 on lipid deposition in WRL68 cells Xianglan Lei, Yuxuan Peng, Yan Li, Qianyuan Chen, Zhenguo Shen, Wen Yin, Viktar Lemiasheuski, Siyang Xu, Jin He Bioorganic Chemistry.2024; 145: 107165. CrossRef
Effects of dietary supplementation of fish oil plus vitamin D3 on gut microbiota and fecal metabolites, and their correlation with nonalcoholic fatty liver disease risk factors: a randomized controlled trial Xueqi Li, Chi Pan, Wenjun Ma, Ting Yang, Chong Wang, Weiwei Han, Wei Zhang, Hui Li, Zhongxia Li, Ting Zhao, Xiao-fei Guo, Duo Li Food & Function.2024; 15(5): 2616. CrossRef
New aspects characterizing non-obese NAFLD by the analysis of the intestinal flora and metabolites using a mouse model Wenji Zhang, Wenli Cheng, JingHui Li, Zhenrui Huang, Hui Lin, Wenjuan Zhang, Rosie Alegado mSystems.2024;[Epub] CrossRef
Differences among Lactiplantibacillus plantarum strains isolated from different fermented foods in their potential cholesterol-lowering properties Shu-Jun Guo, Chang-Cheng Li, Yu-Ting Feng, Yan-Ru Zhou, Bin Liu, Zhen-Peng Gao, Chun-Feng Guo Food Bioscience.2024; 59: 103847. CrossRef
Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001–2023) Xiaofei Zhu, Ziyuan Zhou, Xiaxia Pan Frontiers in Microbiology.2024;[Epub] CrossRef
Semaglutide alters gut microbiota and improves NAFLD in db/db mice Tuohua Mao, Chenxuan Zhang, Shuang Yang, Yingying Bi, Man Li, Jia Yu Biochemical and Biophysical Research Communications.2024; 710: 149882. CrossRef
Bacterial Community Influences the Effects of Lactobacillus acidophilus on Lipid Metabolism, Immune Response, and Antioxidant Capacity in Dogs Aipeng Mao, Xiaoli Chen, Weigang Zhao, Weixiao Nan, Yao Huang, Yalong Sun, Haihua Zhang, Chao Xu Animals.2024; 14(9): 1257. CrossRef
Impact of Synbiotic Intake on Liver Metabolism in Metabolically Healthy Participants and Its Potential Preventive Effect on Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD): A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial Aakash Mantri, Anika Köhlmoos, Daniela Stephanie Schelski, Waldemar Seel, Birgit Stoffel-Wagner, Peter Krawitz, Peter Stehle, Jens Juul Holst, Bernd Weber, Leonie Koban, Hilke Plassmann, Marie-Christine Simon Nutrients.2024; 16(9): 1300. CrossRef
Therapeutic potential of Lactobacillus casei and Chlorella vulgaris in high-fat diet-induced non-alcoholic fatty liver disease (NAFLD)-associated kidney damages: a stereological study Haniyeh Keyghobadi, Hadis bozorgpoursavadjani, Farhad Koohpeyma, Nazanin Mohammadipoor, Marzieh Nemati, Farshad Dehghani, Iman Jamhiri, Gholamhossein Keighobadi, Sanaz Dastghaib Molecular Biology Reports.2024;[Epub] CrossRef
Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study Nicolás Ortiz-López, Ana María Madrid, Larissa Aleman, Alejandra Zazueta, Gladys Smok, Lucía Valenzuela-Pérez, Jaime Poniachik, Caroll J. Beltrán Frontiers in Medicine.2024;[Epub] CrossRef
NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options Natalia G. Vallianou, Dimitris Kounatidis, Sotiria Psallida, Nikolaos Vythoulkas-Biotis, Andreas Adamou, Tatiana Zachariadou, Sofia Kargioti, Irene Karampela, Maria Dalamaga Metabolites.2024; 14(7): 366. CrossRef
Integrated serum metabolomics, 16S rRNA sequencing and bile acid profiling to reveal the potential mechanism of gentiopicroside against nonalcoholic steatohepatitis in lean mice Zeyun Li, Xueya Zhu, Chenhao Li, Ruiting Tang, Yuanyuan Zou, Shuaibing Liu Journal of Ethnopharmacology.2024; 334: 118526. CrossRef
Vinpocetine and Lactobacillus improve fatty liver in rats: role of adiponectin and gut microbiome Ahmed M. El-Baz, Ahmed Shata, Nehal A. Nouh, Lubna Jamil, Mohamed M. Hafez, Sally Negm, Attalla F. El-kott, Mohammed A. AlShehri, Eman M. Khalaf AMB Express.2024;[Epub] CrossRef
Physiological Effects of Lactic Acid Bacteria on Induced Non-Alcoholic Fatty Liver Disease in Male Laboratory Rats Mohammed F. Ayyed, Feryal F. Hussein, Mohammed J. Mohammed IOP Conference Series: Earth and Environmental Science.2024; 1371(6): 062019. CrossRef
Impact of Lactobacillaceae supplementation on the multi-organ axis during MASLD André A. Santos, Raquel Duarte, Madalena Duarte, Fabiola Arella, Vanda Marques, Stefan Roos, Cecília M.P. Rodrigues Life Sciences.2024; 354: 122948. CrossRef
Gut Microbiome and Metabolome Alterations in Overweight or Obese Adult Population after Weight-Loss Bifidobacterium breve BBr60 Intervention: A Randomized Controlled Trial Zhouya Bai, Ying Wu, Dejiao Gao, Yao Dong, Yujia Pan, Shaobin Gu International Journal of Molecular Sciences.2024; 25(20): 10871. CrossRef
The influence of perilipin 5 deficiency on gut microbiome profiles in murine metabolic dysfunction-associated fatty liver disease (MAFLD) and MAFLD-hepatocellular carcinoma Marinela Krizanac, Paula Štancl, Paola Berenice Mass-Sanchez, Rosa Karlić, Diana Moeckel, Twan Lammers, Anastasia Asimakopoulos, Ralf Weiskirchen Frontiers in Cellular and Infection Microbiology.2024;[Epub] CrossRef
Association between hepatocyte TM4SF5 expression and gut microbiome dysbiosis during non-alcoholic fatty liver disease development Yangie Dwi Pinanga, Kyung-hee Pyo, Eun-Ae Shin, Haesong Lee, Eun Hae Lee, Wonsik Kim, Soyeon Kim, Ji Eon Kim, Semi Kim, Jung Weon Lee Life Sciences.2024; 358: 123164. CrossRef
Copper oxide nanoparticles induce non-alcoholic fatty liver disease by disrupting bile acid homeostasis and perturbing the intestinal microbial homeostasis Muran Jiang, Xiaoqi Tao, Yingxin Pang, Zongmin Qin, Erqun Song, Yang Song Journal of Hazardous Materials.2024; 480: 136416. CrossRef
Timing Matters: Late, but Not Early, Exercise Training Ameliorates MASLD in Part by Modulating the Gut‐Liver Axis in Mice Artemiy Kovynev, Zhixiong Ying, Sen Zhang, Emanuele Olgiati, Joost M. Lambooij, Clara Visentin, Bruno Guigas, Quinten R. Ducarmon, Patrick C. N. Rensen, Milena Schönke Journal of Pineal Research.2024;[Epub] CrossRef
The probiotic Lacticaseibacillus rhamnosus SD11 alleviates the progression of liver and colon damage through modulation of inflammation and tight junction proteins in streptozotocin-induced diabetic mice Waraporn Ruathong, Pissared Khuituan, Saranya Peerakietkhajorn, Rawee Teanpaisan, Jongdee Nopparat, Sayed Haidar Abbas Raza PLOS ONE.2024; 19(11): e0313395. CrossRef
Gut ecological networks reveal associations between bacteria, exercise, and clinical profile in non-alcoholic fatty liver disease patients Susanne Csader, Xiuqiang Chen, Howell Leung, Ville Männistö, Heikki Pentikäinen, Milla-Maria Tauriainen, Kai Savonen, Hani El-Nezami, Ursula Schwab, Gianni Panagiotou, Marc D. Cook mSystems.2023;[Epub] CrossRef
Tetrastigma hemsleyanumleaf extracts ameliorate NAFLD in mice with low-grade colitisviathe gut–liver axis Lihua Xiao, Hua Xiong, Zeyuan Deng, Xin Peng, Kejun Cheng, Hua Zhang, Li Jiang, Yong Sun Food & Function.2023; 14(1): 500. CrossRef
Protective Effects of Lactobacillus gasseri against High-Cholesterol Diet-Induced Fatty Liver and Regulation of Host Gene Expression Profiles Tianhua He, Nikita Lykov, Xu Luo, Huiling Wang, Zhanxiang Du, Ziyi Chen, Shitian Chen, Lin Zhu, Ye Zhao, Chimeng Tzeng International Journal of Molecular Sciences.2023; 24(3): 2053. CrossRef
Dendrobium officinale alleviates high-fat diet-induced nonalcoholic steatohepatitis by modulating gut microbiota Gege Tian, Wei Wang, Enrui Xia, Wenhui Chen, Shunzhen Zhang Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
Effects of SCFAs and TMAO on non-alcoholic fatty liver disease indicating the therapeutic benefits of plant-based diet, and supplemental prebiotics, probiotics and synbiotics Vuong Vu, Young Mee Kim, Moonjae Cho Applied Biological Chemistry.2023;[Epub] CrossRef
Limosilactobacillus fermentum MG4294 and Lactiplantibacillus plantarum MG5289 Ameliorates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced Mice Ji Yeon Lee, Minju An, Huijin Heo, Jeong-Yong Park, Junsoo Lee, Chang-Ho Kang Nutrients.2023; 15(8): 2005. CrossRef
Probiotics as Potential Therapy in the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) Margalida Monserrat-Mesquida, Cristina Bouzas, Catalina M. Mascaró, Silvia Tejada, Antoni Sureda Fermentation.2023; 9(4): 395. CrossRef
Ameliorating effect of probiotic on nonalcoholic fatty liver disease and lipolytic gene expression in rabbits Marina Aziz, Shabaan A. Hemeda, Ghadeer M. Albadrani, Sabreen E. Fadl, Fatma Elgendey Scientific Reports.2023;[Epub] CrossRef
Therapeutic mechanisms of the medicine and food homology formula Xiao-Ke-Yin on glucolipid metabolic dysfunction revealed by transcriptomics, metabolomics and microbiomics in mice Mei Li, Ding Cheng, Chuan Peng, Yujiao Huang, Jie Geng, Guangrui Huang, Ting Wang, Anlong Xu Chinese Medicine.2023;[Epub] CrossRef
Supplementation of Lactobacillus plantarum ATCC14917 mitigates non-alcoholic fatty liver disease in high-fat-diet-fed rats Xingjian Wen, Hejing Liu, Xiaoling Luo, Li Lui, Jiuyu Fan, Yajing Xing, Jia Wang, Xingfang Qiao, Na Li, Guixue Wang Frontiers in Microbiology.2023;[Epub] CrossRef
MicroRNA‐29a Compromises Hepatic Adiposis and Gut Dysbiosis in High Fat Diet‐Fed Mice via Downregulating Inflammation Ya‐Ling Yang, Ying‐Hsien Huang, Feng‐Sheng Wang, Ming‐Chao Tsai, Chien‐Hung Chen, Wei‐Shiung Lian Molecular Nutrition & Food Research.2023;[Epub] CrossRef
Brown adipose tissue-derived Nrg4 alleviates non-alcoholic fatty liver disease in mice Jing Luo, Ming Chen, Hongwu Ji, Weifeng Su, Wenkui Song, Di Zhang, Weiming Su, Shucheng Liu Journal of Functional Foods.2023; 108: 105735. CrossRef
Sanguisorba officinalis L. Ameliorates Hepatic Steatosis and Fibrosis by Modulating Oxidative Stress, Fatty Acid Oxidation, and Gut Microbiota in CDAHFD-Induced Mice Yunseong Nam, Myungsuk Kim, Saruul Erdenebileg, Kwang Hyun Cha, Da Hye Ryu, Ho Youn Kim, Su Hyeon Lee, Je Hyeong Jung, Chu Won Nho Nutrients.2023; 15(17): 3779. CrossRef
The PKA‐SREBP1c Pathway Plays a Key Role in the Protective Effects of Lactobacillus johnsonii JNU3402 Against Diet‐Induced Fatty Liver in Mice Eunjeong Hong, Hyuno Kang, Garam Yang, Sejong Oh, Eungseok Kim Molecular Nutrition & Food Research.2023;[Epub] CrossRef
Metagenomic signatures reveal the key role of phloretin in amelioration of gut dysbiosis attributed to metabolic dysfunction-associated fatty liver disease by time-dependent modulation of gut microbiome Jyoti Chhimwal, Prince Anand, Priyanka Mehta, Mohit Kumar Swarnkar, Vikram Patial, Rajesh Pandey, Yogendra Padwad Frontiers in Microbiology.2023;[Epub] CrossRef
Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance Kyoung Jin Choi, Mi Young Yoon, Ji-Eun Kim, Sang Sun Yoon Scientific Reports.2023;[Epub] CrossRef
Lactobacillus plantarum ameliorates NASH-related inflammation by upregulating l-arginine production Dong Yun Kim, Jun Yong Park, Heon Yung Gee Experimental & Molecular Medicine.2023; 55(11): 2332. CrossRef
Amlodipine, an anti‐hypertensive drug, alleviates non‐alcoholic fatty liver disease by modulating gut microbiota Yang Li, Danyang Zhao, Minyi Qian, Jun Liu, Chuyue Pan, Xinxin Zhang, Xubin Duan, Yufei Zhang, Wenxin Jia, Lirui Wang British Journal of Pharmacology.2022; 179(9): 2054. CrossRef
The Lactobacillus as a Probiotic: Focusing on Liver Diseases Jin-Ju Jeong, Hee Jin Park, Min Gi Cha, Eunju Park, Sung-Min Won, Raja Ganesan, Haripriya Gupta, Yoseph Asmelash Gebru, Satya Priya Sharma, Su Been Lee, Goo Hyun Kwon, Min Kyo Jeong, Byeong Hyun Min, Ji Ye Hyun, Jung A Eom, Sang Jun Yoon, Mi Ran Choi, Don Microorganisms.2022; 10(2): 288. CrossRef
Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role Haripriya Gupta, Byeong-Hyun Min, Raja Ganesan, Yoseph Asmelash Gebru, Satya Priya Sharma, Eunju Park, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Ji-Ye Hyun, Jung-A. Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Do Biomedicines.2022; 10(3): 550. CrossRef
Modulatory effects of phenolics extract of Costus afer leaves on cadmium induced nephrotoxicity and hepatoxicity in Wistar rats Tope Gafar Atere, O. O. Oladokun, O. S. Osuntokun, K. I. Adedokun, J. O. Fatoki, S. A. Olawumi, O. S. Tokunbo, O. O. Obembe, O. S. Afolabi Toxicology and Environmental Health Sciences.2022; 14(2): 157. CrossRef
Usefulness of Probiotics in the Management of NAFLD: Evidence and Involved Mechanisms of Action from Preclinical and Human Models Laura Arellano-García, María P. Portillo, J. Alfredo Martínez, Iñaki Milton-Laskibar International Journal of Molecular Sciences.2022; 23(6): 3167. CrossRef
Docosahexaenoic acid-rich fish oil alleviates hepatic steatosis in association with regulation of gut microbiome in ob/ob mice Mohammed Said Moose Al-Bulish, Wanxiu Cao, Ruili Yang, Yuming Wang, Changhu Xue, Qingjuan Tang Food Research International.2022; 157: 111373. CrossRef
Walnut green husk ethanol extract improves gut microbiota and their metabolites associated with NLRP3 in non-alcoholic steatohepatitis Qionglian Fang, Xinping Li, Mengmeng Wang, Xue Qiao, Feng Huang, Chunyan Hu, Yongmei Xue, Shenglan Zhao, Yuping Lin Food & Function.2022; 13(11): 6387. CrossRef
Resilience and the Gut Microbiome: Insights from Chronically Socially Stressed Wild-Type Mice Malena dos Santos Guilherme, Francesco Valeri, Jennifer Winter, Marianne B. Müller, Andreas Schwiertz, Kristina Endres Microorganisms.2022; 10(6): 1077. CrossRef
The Potential Effect of Intestinal Flora and Metabolites on High-Fat Diet-Mediated Nonalcoholic Fatty Liver Disease 志伟 韩 Advances in Clinical Medicine.2022; 12(05): 4823. CrossRef
Gut microbiota mediates methamphetamine-induced hepatic inflammation via the impairment of bile acid homeostasis Kai-Kai Zhang, Jia-Li Liu, Li-Jian Chen, Jia-Hao Li, Jian-Zheng Yang, Ling-Ling Xu, Yu-Kui Chen, Qin-Yao Zhang, Xiu-Wen Li, Yi Liu, Dong Zhao, Xiao-Li Xie, Qi Wang Food and Chemical Toxicology.2022; 166: 113208. CrossRef
A Transcriptomic Response to Lactiplantibacillus plantarum-KCC48 against High-Fat Diet-Induced Fatty Liver Diseases in Mice Ilavenil Soundharrajan, Muthusamy Karnan, Jeong-Sung Jung, Kyung-Dong Lee, Jeong-Chae Lee, Thiyagarajan Ramesh, Dahye Kim, Ki-Choon Choi International Journal of Molecular Sciences.2022; 23(12): 6750. CrossRef
Gut Commensal Parabacteroides goldsteinii MTS01 Alters Gut Microbiota Composition and Reduces Cholesterol to Mitigate Helicobacter pylori-Induced Pathogenesis Chih-Ho Lai, Tzu-Lung Lin, Mei-Zi Huang, Shiao-Wen Li, Hui-Yu Wu, Ya-Fang Chiu, Chia-Yu Yang, Cheng-Hsun Chiu, Hsin-Chih Lai Frontiers in Immunology.2022;[Epub] CrossRef
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim Clinical and Molecular Hepatology.2022; 28(3): 425. CrossRef
Total Flavonoids from Chimonanthus nitens Oliv. Leaves Ameliorate HFD-Induced NAFLD by Regulating the Gut–Liver Axis in Mice Wenya Meng, Zitong Zhao, Lingli Chen, Suyun Lin, Yang Zhang, Jing He, Kehui Ouyang, Wenjun Wang Foods.2022; 11(14): 2169. CrossRef
Effects of garlic and its major bioactive components on non-alcoholic fatty liver disease: A systematic review and meta-analysis of animal studies Sara Shojaei-Zarghani, Mohammad Reza Fattahi, Asma Kazemi, Ali Reza Safarpour Journal of Functional Foods.2022; 96: 105206. CrossRef
Investigation of Gynura segetum root extract (GSrE) induced hepatotoxicity based on metabolomic signatures and microbial community profiling in rats Xinyi Gu, Shuwei Li, Mengna Lu, Ying Li, Qixue Wang, Long Chen, Yiqun Jia, Shan Cao, Ting Zhang, Mingmei Zhou, Xiaojun Gou Frontiers in Microbiology.2022;[Epub] CrossRef
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin, Jinbo Yang Signal Transduction and Targeted Therapy.2022;[Epub] CrossRef
Depletion of Gut Microbiota Inhibits Hepatic Lipid Accumulation in High-Fat Diet-Fed Mice Hui Han, Mengyu Wang, Ruqing Zhong, Bao Yi, Martine Schroyen, Hongfu Zhang International Journal of Molecular Sciences.2022; 23(16): 9350. CrossRef
The Functional Roles of Lactobacillus acidophilus in Different Physiological and Pathological Processes Huijuan Gao, Xin Li, Xiatian Chen, Deng Hai, Chuang Wei, Lei Zhang, Peifeng Li Journal of Microbiology and Biotechnology.2022; 32(10): 1226. CrossRef
Adlay (Coix lacryma‐jobi L.) Polyphenol Improves Hepatic Glucose and Lipid Homeostasis through Regulating Intestinal Flora via AMPK Pathway Shengsuo Ma, Bing Yang, Yucong Shi, Yang Du, Yiwen Lv, Jiarong Liu, Enyan Liu, Huachong Xu, Li Deng, Xiao‐yin Chen Molecular Nutrition & Food Research.2022;[Epub] CrossRef
Dysregulated hepatic lipid metabolism and gut microbiota associated with early-stage NAFLD in ASPP2-deficiency mice Fang Xie, Hang-fei Xu, Jing Zhang, Xiao-ni Liu, Bu-xin Kou, Meng-yin Cai, Jing Wu, Jin-ling Dong, Qing-hua Meng, Yi Wang, Dexi Chen, Yang Zhang Frontiers in Immunology.2022;[Epub] CrossRef
Triglyceride: A mediator of the association between waist-to-height ratio and non-alcoholic fatty liver disease: A second analysis of a population-based study Haofei Hu, Yong Han, Yufei Liu, Mijie Guan, Qijun Wan Frontiers in Endocrinology.2022;[Epub] CrossRef
Genetic variants associated with circulating liver injury markers in Mexican Americans, a population at risk for non-alcoholic fatty liver disease Caroline M. Sabotta, Suet-Ying Kwan, Lauren E. Petty, Jennifer E. Below, Aron Joon, Peng Wei, Susan P. Fisher-Hoch, Joseph B. McCormick, Laura Beretta Frontiers in Genetics.2022;[Epub] CrossRef
Role of Akkermansia muciniphila in the development of nonalcoholic fatty liver disease: current knowledge and perspectives Yuqiu Han, Lanjuan Li, Baohong Wang Frontiers of Medicine.2022; 16(5): 667. CrossRef
Lactobacillus Species as Probiotics: Isolation Sources and Health Benefits Ameera M. Al-Yami, Abeer T. Al-Mousa, Sarah A. Al-Otaibi, Ashraf Y. Khalifa Journal of Pure and Applied Microbiology.2022; 16(4): 2270. CrossRef
Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try Tian-Yi Ren, Xiao-Yan Li, Jian-Gao Fan Clinical and Molecular Hepatology.2021; 27(1): 83. CrossRef
Aryl Hydrocarbon Receptor (AhR) Activation by 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) Dose-Dependently Shifts the Gut Microbiome Consistent with the Progression of Non-Alcoholic Fatty Liver Disease Russell R. Fling, Timothy R. Zacharewski International Journal of Molecular Sciences.2021; 22(22): 12431. CrossRef
Mykotherapie bei Fettstoffwechselstörungen – wertvoller Beitrag von Vitalpilzen Dorothee Bös Erfahrungsheilkunde.2021; 70(05): 264. CrossRef
Isolation and Purification of β-Galactosidase Enzyme From Local Lactic Acid Bacteria Isolates to Overcome The Phenomenon of Non-Degradation of Milk Lactose Aisha A. Juma, Amin S. Badawy, Sanad B. Mohammed IOP Conference Series: Earth and Environmental Science.2021; 910(1): 012075. CrossRef
The probiotic effects of AB23A on high-fat-diet-induced non-alcoholic fatty liver disease in mice may be associated with suppressing the serum levels of lipopolysaccharides and branched-chain amino acids Fan Xia, Shijian Xiang, Zhijuan Chen, Luyao Song, Yuxin Li, Ziqiong Liao, Bingchen Ge, Benjie Zhou Archives of Biochemistry and Biophysics.2021; 714: 109080. CrossRef
Severe alcoholic hepatitis (AH) is an acute and often devastating form of alcohol-associated liver disease. Clinically, AH is characterized by elevated bilirubin, model for end stage liver disease scores >20, and nonspecific symptoms that are caused by underlying inflammation, hepatocyte injury, and impaired intestinal barrier function. Compromised immune defense in AH contributes to infections, sepsis and organ failure. To date, corticosteroids are the only recommended treatment for severe AH, however it does not provide survival benefits beyond 1 month. Recent preclinical and early clinical studies in AH aided understanding of the disease and presented opportunities for new therapeutic options targeting inflammation, oxidative stress, liver regeneration and modification of intestinal microbiota. In this comprehensive review, we discuss promising preclinical results and ongoing clinical trials evaluating novel therapeutic agents for the treatment of severe AH.
Citations
Citations to this article as recorded by
Chronic alcohol and liver health: The gut-liver axis as a therapeutic target Dakshina M. Nair, Leela Kakithakara Vajravelu, Poornima Baskar Vimala, Rahul Harikumar Lathakumari, Vishnupriya Paneerselvam, Jayaprakash Thulukanam Gastroenterology & Endoscopy.2026; 4(1): 38. CrossRef
Therapeutic potential of gallic acid and diosgenin in metabolic dysfunction-associated steatotic liver disease (MASLD) and non-alcoholic fatty liver disease (NAFLD): A comprehensive review Trilochan Satapathy, Mansi Verma, Poonam Sahu, Anjali Minj Pharmacological Research - Natural Products.2026; 10: 100525. CrossRef
Therapeutic Mechanisms of Lactiplantibacillus plantarum NXU0014 Against Chronic Alcohol‐Induced Liver Injury Mediated by Gut‐Liver Axis Modulation Quan Ji, Yanhong Wang, Longxuan Huo, Chen Qiao, Fuqi Li, Fan Yang, Lin Pan Molecular Nutrition & Food Research.2026;[Epub] CrossRef
Longitudinal assessment of the circulating cytokine profile of severe alcohol-associated hepatitis David Tornai, Mack C. Mitchell, Craig J. McClain, Srinivasan Dasarathy, Bruce Barton, Gyongyi Szabo Hepatology.2026;[Epub] CrossRef
Prospective study on time-to-tertiary care in alcohol-associated hepatitis: space–time coordinates as prognostic tool and therapeutic target Ľubomír Skladaný, Daniela Žilinčanová, Natália Kubánek, Svetlana Adamcová Selčanová, Daniel Havaj, Lukáš Laffers, Michal Žilinčan, Alvi H Islam, Juan Pablo Arab, Tomáš Koller Alcohol and Alcoholism.2025;[Epub] CrossRef
Larsucosterol for the Treatment of Alcohol-Associated Hepatitis Mitchell Shiffman, Ben Da, Aparna Goel, Allison Kwong, Lance Stein, Christophe Moreno, Amanda Nicoll, Ashwini Mehta, Alexandre Louvet, Steven Flamm, Nikolaos Pyrsopoulos, Sanjaya Satapathy, Alexander Kuo, Daniel Ganger, Costica Aloman, Simone I. Strasser, NEJM Evidence.2025;[Epub] CrossRef
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics Xiao Ma, Tengda Huang, Xiangzheng Chen, Qian Li, Mingheng Liao, Li Fu, Jiwei Huang, Kefei Yuan, Zhen Wang, Yong Zeng Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
New prognostic model for hospitalized patients with alcoholic cirrhosis and Maddrey’s discriminant function <32 Tae Hyung Kim, Hyung Joon Yim, Young Kul Jung, Do Seon Song, Eileen L. Yoon, Hee Yeon Kim, Seong Hee Kang, Young Chang, Jeong-Ju Yoo, Baek Gyu Jun, Sung Won Lee, Jung Gil Park, Ji Won Park, Sung-Eun Kim, Tae Yeob Kim, Soung Won Jeong, Ki Tae Suk, Moon You Hepatology International.2024; 18(2): 500. CrossRef
Review article: Hepatic steatosis and its associations with acute and chronic liver diseases Aaron B. Koenig, Albert Tan, Hala Abdelaal, Fanny Monge, Zobair M. Younossi, Zachary D. Goodman Alimentary Pharmacology & Therapeutics.2024; 60(2): 167. CrossRef
Pathogenesis of Alcohol-Associated Liver Disease Pranoti Mandrekar, Abhishek Mandal Clinics in Liver Disease.2024; 28(4): 647. CrossRef
3PM-guided innovation in treatments of severe alcohol-associated hepatitis utilizing fecal microbiota transplantation Lubomir Skladany, Natalia Kubanek, Svetlana Adamcova Selcanova, Daniela Zilincanova, Daniel Havaj, Karolina Sulejova, Katarina Soltys, Lucia Messingerova, Michal Lichvar, Lukas Laffers, Michal Zilincan, Eva Honsova, Peter Liptak, Peter Banovcin, Jan Bures EPMA Journal.2024; 15(4): 677. CrossRef
Alcohol-Related Liver Disease Including New Developments Parita Virendra Patel, Steven L. Flamm Clinics in Liver Disease.2023; 27(1): 157. CrossRef
Role of rifaximin in the management of alcohol‐associated hepatitis: A systematic review and meta‐analysis Zohaib Ahmed, Joyce Badal, Mohamad Nawras, Dhanushya Battepati, Umer Farooq, Syeda Faiza Arif, Wade Lee‐Smith, Muhammad Aziz, Umair Iqbal, Ahmad Nawaz, Manesh Kumar Gangwani, Amna Iqbal, Abdallah Kobeissy, Benyam D Addissie, Mona Hassan, Sammy Saab Journal of Gastroenterology and Hepatology.2023; 38(5): 703. CrossRef
Current and emerging therapies for alcohol-associated hepatitis Francisco Idalsoaga, Gustavo Ayares, Luis Antonio Díaz, Jorge Arnold, María Ayala-Valverde, David Hudson, Marco Arrese, Juan Pablo Arab Liver Research.2023; 7(1): 35. CrossRef
Tgr5 −/− mice are protected from ethanol-induced metabolic alterations through enhanced leptin and Fgf21 signaling Sabita Pokhrel, Matthew Dilts, Zachary Stahl, Shannon Boehme, Gabrielle Frame, John Y.L. Chiang, Jessica M. Ferrell Hepatology Communications.2023;[Epub] CrossRef
Therapeutic targets in alcohol-associated liver disease: progress and challenges Ayooluwatomiwa Deborah Adekunle, Adeyinka Adejumo, Ashwani K. Singal Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
A Review on “IL-1 Receptor Antagonist Plus Pentoxifylline and Zinc for Severe Alcohol-Associated Hepatitis” Shrihari Anikhindi, Akshay Anikhindi, Ashish Kumar, Anil Arora Journal of Clinical and Experimental Hepatology.2023; 13(3): 533. CrossRef
A novel score of IL-13 and age predicts 90-day mortality in severe alcohol-associated hepatitis: A multicenter plasma biomarker analysis David Tornai, Mack Mitchell, Craig J. McClain, Srinivasan Dasarathy, Arthur McCullough, Svetlana Radaeva, Aimee Kroll-Desrosiers, JungAe Lee, Bruce Barton, Gyongyi Szabo Hepatology Communications.2023;[Epub] CrossRef
Current Medical Treatment for Alcohol-Associated Liver Disease Gustavo Ayares, Francisco Idalsoaga, Luis A. Díaz, Jorge Arnold, Juan P. Arab Journal of Clinical and Experimental Hepatology.2022; 12(5): 1333. CrossRef
Transplant in acute alcoholic hepatitis: a relative contraindication Neha Jakhete, Ameer Abutaleb, Kirti Shetty Current Opinion in Organ Transplantation.2022; 27(2): 93. CrossRef
Mesenchymal stem cells-based therapy in liver diseases Heng-Tong Han, Wei-Lin Jin, Xun Li Molecular Biomedicine.2022;[Epub] CrossRef
The role of gut microbiota in liver regeneration Zhe Xu, Nan Jiang, Yuanyuan Xiao, Kefei Yuan, Zhen Wang Frontiers in Immunology.2022;[Epub] CrossRef
Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives Yoonji Ha, Inju Jeong, Tae Hyun Kim Biomedicines.2022; 10(10): 2530. CrossRef
Innate immune activation: Parallels in alcohol use disorder and Alzheimer’s disease Adriana Ramos, Radhika S. Joshi, Gyongyi Szabo Frontiers in Molecular Neuroscience.2022;[Epub] CrossRef
Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives Szu-Yi Liu, I-Ting Tsai, Yin-Chou Hsu International Journal of Molecular Sciences.2021; 22(10): 5170. CrossRef
First
Prev
